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S-01 The importance of breast cancer research from a patient’s view: the voices and visions of
advocates
S Leigh
Past President, National Coalition for Cancer Survivorship, Cancer Survivorship Consultant, Tucson, Arizona, USA
While advances in science and technology have
increased options for treating breast cancer, current social
trends have changed the way people deal with this
disease. Women in the United States are no longer simply
passive patients, but rather they are survivors, advocates
and activists who are speaking up for themselves and
speaking out for issues relevant to the treatment and pre-
vention of breast cancer.
As the discoveries of basic science have been translated
to better clinical treatment, a new sense of hope has
emerged. Quality of life now shares the spotlight with
quantity of life as breast cancer has shifted from an acute
to a chronic condition and as the numbers of long-term
survivors increase. While this new population tends to
have more optimistic expectations for survival, they are
also expressing concerns about issues affecting their lives
through and beyond treatment. These issues include, but
are not limited to, such concerns as efficient and accurate
diagnosis, the complexity of treatment decisions, access
to quality cancer care, informed consent, privacy issues,
availability of supportive care treatments, and effective
communication skills, especially with their physicians. Sur-
vivors are also concerned about the impact of their
disease on spouses and family, on fertility and sexuality
issues, on their employment and (in the USA) insurability,
and on their long-term survival. The identification of these
increasing issues has given rise to a consumer movement
that encourages a shift away from powerless victim to
empowered survivor.
Historically, breast cancer advocates asked for increased
educational and supportive care resources. As the sur-
vivorship movement matured, new responsibilities and dif-
fering agendas arose amongst these groups. Some
organizations defined their mission as one that would raise
funds to support scientific research. Others felt compelled
to raise awareness about early detection and treatment,
controversial environmental issues, and prevention or risk
reduction. A few organizations later entered the more
political arenas and began lobbying for issues related to
health care delivery, clinical trials access, and quality
cancer care. Meanwhile, these many and varied missions
are all helping to define an international agenda for breast
cancer research and care, to guarantee the inclusion of
consumer voices in most levels of decision-making, and to
create partnerships between patients with breast cancer
and the professionals who care for them.
S-02 Abstract not submitted for publication
S-03 Abstract not submitted for publication
S-04 Genetic testing for BRCA1 and BRCA2 mutations – ready for implementation?
BL Weber
University of Pennsylvania, Philadelphia, PA, USA
With the discovery of BRCA1 and BRCA2, testing for
germline mutations became a possibility. However, there are
several questions that must be considered if genetic testing
is to be widely implemented. First, who should have the test
– are there defined groups at increased risk? Second, is the
laboratory technically capable of accurate testing and with
what sensitivity and specificity? Are the test results inter-
pretable? Finally, is there clinical utility to the test? That is,
are there interventions as a result of the test that will benefit
the patient, and do the benefits outweigh the risks?
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At least partial answers to these questions are now avail-
able. There are well-established methods of identifying
mutations, and there are known founder mutations that sim-
plify testing in some populations. In particular, there are data
that suggest that screening all Ashkenazi Jewish women for
the three founder mutations in this group may significantly
reduce deaths from ovarian cancer in this population. Direct
sequencing and heteroduplex analysis are both methods
with sensitivity well over 90% for coding region and splice
site mutations; however, the problem of genomic rearrange-
ments in BRCA1 remains. Variants of uncertain significance
remain a problem, particularly in BRCA2, but truncating
mutations are clearly associated with a markedly increased
risk of breast and ovarian cancer. Perhaps most importantly,
recent work is beginning to provide justification for preven-
tion strategies for both breast and ovarian cancer, as well as
evidence that genetic testing is well-tolerated psychologi-
cally. Finally, most Western countries have addressed the
issue of genetic discrimination and offer protection through
either nationalized health services or federal legislation. In
summary, the past five years have yielded advances in all
areas pertaining to genetic susceptibility testing, and the
promise of cancer prevention associated with the isolation
of BRCA1 and BRCA2 is becoming a reality.
S-05 The pathology of inherited breast tumours
M Stratton
Institute of Cancer Research, UK
There is now a considerable body of information pertaining
to the histopathological appearances of breast cancers
arising in multiple case families due to germline mutations
in breast cancer susceptibility genes. The evidence indi-
cates that cancers in BRCA1 and BRCA2 mutation carri-
ers differ overall in morphological indices seen by H+E
staining from each other, and also from age-matched cases
unselected for family history. BRCA1 cancers differ much
more substantially from controls than BRCA2 cancers and
overall are of higher grade. Differences between these
groups are also seen immunohistochemically for a number
of proteins. Notably, BRCA1 cancers are rarely ER positive
compared to BRCA2 and controls. Cancers from families
not due to either known gene but which are likely to be due
to other, currently unknown susceptibility genes, also differ
from BRCA1, BRCA2 and age-matched control cancers.
These cancers are generally low grade lesions with the
suggestion of an excess of lobular carcinoma cases. The
significance of these histological differences with respect
to prognosis remains controversial.
S-06 Molecular characteristics of inherited breast tumors
Å Borg, IA Hedenfalk, J Vallon-Christersson, N Loman, O Johannsson, H Olsson, DJ Duggan, Y Chen, M Bittner,
O-P Kallioniemi and JM Trent
Department of Oncology, Lund University, SE-221 85 Lund; Sweden and Cancer Genetics Branch, National Human Genome
Research Institute, NIH, Bethesda, MD 20892, USA
Germline mutations in genes involved in DNA double-
strand break repair (DSBR) and DNA damage-induced
checkpoint activation are associated with chromosomal
breakage syndromes and (breast) cancer predisposition.
These genes include TP53, CHK2, ATM, NBS1, Mre11
and the two major breast-cancer susceptibility genes
BRCA1 and BRCA2. Breast tumors from BRCA1 and
BRCA2 mutation carriers have explicit histopathological
features and genetic alterations, distinct from other forms
of inherited (BRCAx) and sporadic breast cancer. This
suggests that transformation of DSBR-deficient cells
follows abrogation of specific cell-cycle control and apop-
tosis mechanisms, and results in genetic instability and
tumor progression along distinguishable pathways. Com-
parative genomic hybridization (CGH) analysis may give
hints to the location of such genes by showing frequent
loss of chromosome 4, 5q, 12q, 13q and Xq in BRCA1
tumors, and of 1p, 3p, 6q, 8p, 9p, 11q, 13q and Xq in
BRCA2 tumors. Frequent copy number gains are seen at
1q, 6p, 8q, 10p, 16p and 17q in BRCA1 tumors, and at
1q, 8q, 16p, 17q, 19 and 20q in BRCA2 tumors. By
extending the analyses to the level of gene expression,
using cDNA microarrays containing 6500 sequence-veri-
fied human genes or ESTs, we have shown that BRCA1
and BRCA2 tumors can be separated into distinct clus-
ters by multi-dimensional scaling and hierarchical dendro-
gram analysis of expression data. Genes consistently up-
or downregulated in each group of inherited breast cancer
have been identified, and will be evaluated as diagnostic
tools in new sets of tumors, also on the level of protein
expression. The presumably heterogeneous group of
BRCAx breast tumors exhibits, in general, a less aggres-
sive phenotype, being typically of low malignant grade and
steroid receptor-positive status. Further characterisation of
gene alteration and expression profiles in these tumors
may be used as a complement to traditional linkage analy-
sis in the search for additional breast cancer susceptibility
genes.S-07 Other cancers in BRCA1 and BRCA2 mutation carriers: implications for counselling and follow up
B Ponder
CRC Department of Oncology, University of Cambridge, Cambridge, UK
Data come from the Breast Cancer Linkage Consortium.
The BRCA1 estimates (from 1993) are being updated.
The overall risk of ovarian cancer was estimated as 30%
by age 60 (but the data suggested the possibility, subse-
quently supported by mutation data, of heterogeneity, with
two groups of families with higher and lower risks of
ovarian cancer), and 3- and 4-fold increases in risk of
prostate and colorectal cancer respectively, correspond-
ing to absolute risks of about 5–10% by age 70. The
BRCA2 estimates are more recent and so based on more
extensive data. The estimated cumulative risk of ovarian
cancer is 0.4% by age 50 and 27% by age 70 (again with
evidence of heterogeneity from mutation studies); statisti-
cally significant elevated risks are also observed for
prostate cancer (overall RR 4.65 [7.33 below age 65];
absolute risk 7.5% by age 70); pancreatic cancer (RR
3.51 [5.54 below age 65]; absolute risk 2% by age 70),
gall bladder and biliary cancer (RR 4.97), stomach cancer
(RR 2.59), malignant melanoma (RR 2.58) and cancer of
the oropharynx (RR 2.26, 95% CI 1.09–4.58). There was
no significant increase in risk of colorectal cancer. The
estimated cumulative risk of male breast cancer is 2% by
age 70, but with very wide confidence limits.
These overall risks will differ in individual cases according
to the specific BRCA mutation, and genetic and non-
genetic modifiers. Except possibly for the protective effects
of OC use on ovarian cancer, this information is not ready
to be translated into clinical practice. The main controversy
is around screening for colorectal and prostate cancer. The
balance of risks and benefits is not known for either; there
is no consensus; a BCLC study of prostate screening is
proposed and a colorectal study in BRCA1 carriers may be
appropriate if the risks are confirmed.
S-08 The role of coactivators in oestrogen action
M Brown and JF de Mora
Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
Several classes of coregulatory molecules are felt to play
important roles in cell-type specific responses to oestro-
gens. These ER coactivators include members of the
SWI2/SNF2 chromatin remodelling complexes, histone
acetyltransferases such as p300/CBP, and p160 factors
of the SRC-1 family. We sought to understand more fully
how growth factors modulate oestrogen receptor activity
in both normal oestrogen physiology and the pathogene-
sis of breast cancer. Growth factors are known to stimu-
late the ligand-independent activity of ER through the
activation of MAPK and the direct phosphorylation of ER.
We have now found that the transcriptional stimulatory
activity of the p160 factor AIB1, a gene amplified prefer-
entially in ER-positive breast cancers, is enhanced by
MAPK. We show that AIB1 is a phosphoprotein in vivo
and can be phosphorylated in vitro by MAPK. Finally we
observe that MAPK activation of AIB1 stimulates the
recruitment of p300 and associated histone acetyltrans-
ferase activity. These results suggest that the ability of
growth factors to modulate oestrogen action may be medi-
ated through MAPK activation of the nuclear receptor
coactivator AIB1. In addition they suggest a potential point
of cross-talk between growth-factor signalling pathways
and oestrogen signalling in ER-positive breast cancers.
S-09 Growth regulation and steroid hormone resistance in breast cancer
KB Horwitz
University of Colorado School of Medicine, Endocrinology Division, Denver, CO 80262, USA
Our research focuses on breast cancer, and how the
steroid hormone agonists – estradiol and progesterone –
enhance growth of these tumors. Therefore, their treat-
ment often involves the use of steroid antagonists, which
interfere with deleterious effects of the agonists. Although
tumors often respond well to antagonists initially, and
undergo remission, eventually tumors acquire resistance
to antagonists and resume growing. I will discuss studies
dealing with growth regulatory mechanisms of proges-
terone, focusing on the role of cyclins; cyclin-dependent
kinases and cdk inhibitors; and cross-talk between prog-
esterone and epidermal growth factor (EGF) signaling.
The latter involves analysis of mechanisms by which prog-
esterone and EGF cooperate to activate mitogen-acti-
vated protein kinase (MAPK) and STAT signaling
pathways, and regulate transcription of the cdk inhibitor,
p21. Additionally we show that MAPK phosphorylation of
progesterone receptors, at serine 294, leads to ligand-
dependent receptor downregulation by the ubiquitin-26S
proteasome pathway. I will also describe the isolation and
characterization of transcriptional coactivators and core-
pressors that either enhance or inhibit transcription by
antagonist-occupied steroid receptors. We test the idea
that the ratio of these coregulators determines whether
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tamoxifen is inhibitory or not, using breast cancers taken
from tamoxifen-responsive and -resistant patients.
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S-10 Abstract not submitted for publication
S-11 Estrogen receptors a a and b b in the rodent mammary gland
S Saji*, EV Jensen*, S Nilsson†, T Rylander*, M Warner* and J-Å Gustafsson*
*Department of Medical Nutrition and Biosciences, Karolinska Institute, NOVUM Huddinge University Hospital, S-14186
Huddinge, and †KaroBio AB, NOVUM, S-141 86 Huddinge, Sweden
An obligatory role for estrogen in growth, development,
and functions of the mammary gland is well established,
but the roles of the two estrogen receptors remain
unclear. With the use of specific antibodies, it was found
that both estrogen receptors, ERa and ERb, are
expressed in the rat mammary gland, but the presence
and cellular distribution of the two receptors are distinct.
In prepubertal rats, ERa was detected in 40% of the
epithelial cell nuclei. This decreased to 30% at puberty
and continued to decrease throughout pregnancy to a low
of 5% at day 14. During lactation there was a large induc-
tion of ERa with up to 70% of the nuclei positive at day
21. Approximately 60–70% of epithelial cells expressed
ERb at all stages of breast development. Cells coexpress-
ing ERa and ERb were rare during pregnancy, a prolifera-
tive phase, but they represented up to 60% of the
epithelial cells during lactation, a postproliferative phase.
Western blot analysis and sucrose gradient centrifugation
confirmed this pattern of expression. During pregnancy,
the proliferating cell nuclear antigen was not expressed in
ERa-positive cells but was observed in 3–7% of ERb-con-
taining cells. Because more than 90% of ERb-bearing
cells do not proliferate, and 55–70% of the dividing cells
have neither ERa nor ERb, it is clear that the presence of
these receptors in epithelial cells is not a prerequisite for
estrogen-mediated proliferation.
S-12 Clinical translation of progress in molecular endocrinology
M Dowsett
Academic Department of Biochemistry, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
There has been substantial recent progress in our under-
standing of the molecular mechanism of oestrogen action,
most particularly by the discovery of (i) a second ER (ii)
the role of co-repressors/co-activators (iii) the importance
of conformational change of ER. This has provided insight
into the mode of action of hormonal drugs for breast
cancer, and prompted new ideas about potential resis-
tance mechanisms, new strategies for treatment and pre-
vention, and the development of new drugs. Differential
conformational change of ER by SERMs seems to deter-
mine the specific binding of the receptor to particular
co-activators/co-repressors of gene transcription. Pertur-
bation of this molecular system can provide cells resistant
to tamoxifen through an increased agonist response.
There are clinical data to support an increased agonist
response of tamoxifen as a resistance mechanism in
breast cancer, but there are few clinical laboratory data to
support aberrant co-activator/co-repressor expression as
an important mechanism. Recent in vitro studies indicate
that MCF7 cells may become resistant to oestrogen depri-
vation by acquired hypersensitivity to oestrogen. There are
clinical data to support this mechanism, and new clinical
trials have been designed to determine whether this phe-
nomenon can be utilised in sequential therapy. To achieve
optimal clinical exploitation of the progress in molecular
endocrinology, there is a need for novel clinical trial
design, which will utilise imaging and molecular pathologi-
cal techniques for assessing the molecular response of
tissues. Neoadjuvant treatment of breast cancer offers
unique advantages for such studies. Treatment-induced
changes in proliferation are a useful intermediate end-
point for the evaluation of molecular relationships in breast
carcinomas in vivo and for the assessment of drugs effect-
ing these relationships.
Breast tumors express high levels of type I receptor tyro-
sine kinases and their ligands. This receptor family is com-
posed of four homologue receptors; the epidermal growth
factor receptor (ErbB1/EGF receptor/HER1), ErbB2
(HER2/neu), ErbB3 (HER3), and ErbB4 (HER4). These
receptors are composed of an extracellular binding domain,
S-13 The EGF receptor family as targets for breast cancer therapy
J Baselga
Hospital General Universitari Vall d’Hebron, Barcelona, Spaina transmembrane lipophilic segment, and an intracellular
protein tyrosine kinase domain with a regulatory carboxyl
terminal segment. Several lines of evidence suggest that
these receptors are optimal targets for new anti-cancer
agents, and a series of monoclonal antibodies are currently
being evaluated both in the laboratory and in the clinic.
Agents currently under study include monoclonal antibody
(MAb) C225 directed at the EGFR, tratstuzumab (Her-
ceptin®) directed at the HER2 receptor, and a new family
of specific EGFR tyrosine kinase inhibitors.
Anti-EGFR MAb 225 prevents the binding of the ligands to
the EGFR, blocks ligand-induced activation of the receptor,
and inhibits the growth of cancer cells both in tissue culture
and in human tumor xenografts. Anti-EGFR MAb 225
greatly enhances the antitumor effects of chemotherapeutic
agents active against breast cancer, such as taxol and dox-
orubicin. A human:murine ‘chimeric’ antibody (C225) has
been produced with comparable affinity and antitumor activ-
ity that allows the administration of repeated doses of MAb
either alone or in combination with chemotherapy. Initial
phase I clinical trials of single and multiple dose weekly
administration of C225 have shown that the antibody is safe
and with predictable pharmacology, achieving optimal anti-
body serum levels for a prolonged period of time.
A new family of potent EGFR tyrosine kinase inhibitors
(TKI) has been recently shown to have a high degree of
receptor specificity and very potent antitumor activity in
the laboratory. We are currently conducting a phase I clini-
cal trial with ZD1839, a potent EGFR TKI, in patients with
advanced malignancies. We have observed inhibition in
vivo of receptor function by tumor and skin biopsies, and
anti-responses have been observed.
S-14 Use of the anti HER-2/neu antibody Herceptin in the treatment of human breast cancer:
biological rationale and clinical results
DJ Slamon
Division Hematology-Oncology, UCLA School of Medicine, Revlon/UCLA Women’s Cancer Research Program, Jonsson
Comprehensive Cancer Center, Los Angeles, California, USA
The HER-2/neu proto-oncogene encodes a growth factor
receptor which is overexpressed in 25–30% of human
breast cancers. This pathologic overexpression is associ-
ated with a decreased relapse-free as well as overall survival
in those patients whose tumors contain the alteration. The
overexpression is most often due to amplification in ~95%
of cases. The association between HER-2/neu amplifica-
tion/overexpression and clinical outcome suggested that
the alteration may play a causal role in pathogenesis. To test
the potential role of HER-2/neu overexpression in altering
the biological activity of human breast normal and malignant
epithelial cells, we conducted a number of in vitro studies in
which single-copy, low-expressing cell lines were converted
to multiple-copy, high-expressing cells. The biological
effects of HER-2/neu overexpression were then measured,
including effects on DNA synthesis, cell growth, anchorage-
independent growth, tumorigenicity and metastatic poten-
tial. Overexpression of HER-2/neu resulted in an increase in
those parameters in the malignant cell lines as well as the
non-transformed immortalized breast cell lines. In normal
primary breast cells there was no evidence of these effects
with HER-2/neu overexpression alone.
We also tested the effects of HER-2/neu overexpression
on chemosensitivity to a number of agents. There were no
effects of overexpression on intrinsic sensitivity or resis-
tance to any of nine chemotherapeutic agents, including
anthracycline and taxanes. There were, however, effects
on hormone dependence and tamoxifen sensitivity with a
direct association between HER 2 overexpression and
estrogen independence as well as tamoxifen resistance.
Subsequent to the identification of this alteration and
demonstration of the role it plays in the pathogenesis of
aggressive breast cancers, we tested a number of anti-
body reagents directed against the extracellular domain
of this receptor from a variety of sources. Many of these
antibodies can suppress all of the biological effects
induced by HER-2/neu overexpression both in vitro and
in vivo. Preclinical studies indicate that the antibodies
can be effective in completely suppressing growth of
human tumor cells in vitro, as well as breast cancer
xenografts when either are growing in vivo. The sup-
pression is specific to cells and tissues overexpressing
the HER-2/neu gene. Strategies using anti HER-2/neu
in combination with other therapeutic modalities indi-
cates these antibodies can have additive and occasion-
ally synergistic effects with chemotherapeutic agents
both  in vitro and  in vivo. These observations have led to
the development of new treatment strategies directed at
this molecular alteration, and these strategies have com-
pleted clinical testing. The pivotal phase III study com-
paring best available standard therapy versus best
available plus Herceptin demonstrates that this new bio-
logical agent improves objective response rates by
54%, response duration by 58% and time to progres-
sion by 65%. In addition, initial use of Herceptin as part
of the combination therapy results in a decrease in rela-
tive risk of death by approximately 25% at two and one
half years. The results of this testing have led to the
approval of Herceptin, a therapeutic monoclonal anti-
body effective in HER-2/neu overexpressing breast
cancers.
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S-15 Herceptin in clinical use – early 2000
CL Vogel
University of Miami School of Medicine, USA
Herceptin is the first of a new generation of non-cytotoxic,
non-hormonal compounds showing considerable promise
in the management of metastatic breast cancer. Based on
the seminal work of Slamon and co-workers, the human-
ized monoclonal anti-Her-2-neu antibody entered clinical
trials in the early 1990s. While the initial phase II clinical
trial publication by Baselga and co-workers did not receive
the kind of attention it should have been given, discovery
of activity in heavily pre-treatment patients with the use of
a relatively non-toxic antibody led to further trials establish-
ing the effectiveness of this unique compound.
Two pivotal trials were initiated, with one investigating the
use of Herceptin in patients failing one or two prior
chemotherapy regimens for metastatic breast cancer. In this
trial the response rate was 20% as assessed by the investi-
gator and 14% by an external Response Evaluation Commit-
tee. Patients with 3+ Her-2-neu over-expression appeared to
benefit more (17% vs 7%) than Her-2-neu 2+ over-expres-
sors. Toxicity was mild with fever and chills seen in about
30% of patients, but generally only with the 4 mg/kg loading
dose and seldom with the 2 mg/kg maintenance doses.
In the other pivotal trial, patients were randomized to
chemotherapy alone or with Herceptin as first-line therapy
for metastatic breast cancer. Women who had not received
prior anthracycline therapy were randomized to anthracy-
cline ± Herceptin, while patients with prior adjuvant
anthracycline were randomized to paclitaxel ± Herceptin.
Herceptin plus chemotherapy was superior to chemother-
apy alone in all parameters of effectiveness, including a
5-month survival advantage at two years of follow-up.
S-16 Characterisation of micrometastatic tumor cells
K Pantel
Molecular Oncology, Department of Gynecology and Obstetrics, University Hospital Eppendorf, Hamburg, Germany
Using monoclonal antibodies to epithelial cytokeratins
(CK) or tumor-associated cell membrane glycoproteins,
individual carcinoma cells can be detected on cytological
preparations at frequencies of 10–5 to 10–6 (for review,
see Pantel et al, JNCI, 1999). Our prospective clinical
studies have shown that the presence of these immunos-
tained cells in bone marrow and lymph nodes of patients
without clinical or histopathological signs of metastases is
prognostically relevant (Pantel et al, Lancet, 1996; Izbicki
et al, N Engl J Med, 1997; Braun et al, N Engl J Med,
2000). In addition to immunocytochemistry, new molecular
detection methods based on the amplification of a marker
mRNA species by the polymerase chain reaction tech-
nique have been developed (Zippelius et al, JCO, 1997).
The current assays may be used to improve tumor staging
with potential consequences for adjuvant therapy. Another
promising clinical application is monitoring the response
of micrometastatic cells to adjuvant therapies (Braun et al,
JCO, 2000), which, at present, can only be assessed ret-
rospectively after an extended period of clinical follow-up.
Moreover, the screening methods can be applied to
detect tumor cells in the autologous transplant. The
extremely low frequency of bone marrow tumor cells
greatly hampers approaches to obtain more specific infor-
mation on their biological properties. The tools established
in our laboratory (eg, micrometastatic cell lines, single cell
(RT)PCR, multiple labelling, and FISH) allow one to obtain
further insights into the phenotype and genotype of
therapy-sensitive and resistant micrometastases. The
available data indicate that micrometastatic cells represent
a selected population of cancer cells which, however, still
express a considerable degree of heterogeneity with
regard to chromosomal aberrations and phenotypic prop-
erties. Prominent characteristics of bone marrow tumor
cells at the time of primary tumor diagnosis are the lack of
both p53 mutations and proliferation-associated marker
proteins and the frequent overexpression of the erbB2
oncogene (Pantel et al, JNCI, 1993; Putz et al, Cancer
Res, 1999; Offner et al, PNAS, 1999). Identification of the
molecular determinants of micrometastasis may help to
design new strategies to detect and eliminate minimal
residual cancer.
S-17 Animal models of human tumor suppressor genes
TW Mak
Ontario Cancer Institute, Canada
Tumor suppressor genes are a class of genes found
mutated on both alleles in tumor cells. They are usually impli-
cated in DNA repair, cell-cycle progression, differentiation,
and apoptosis. Their loss of function is involved in the devel-
opment of malignancies. Many of these tumor suppressor
genes are also found mutated in familial cancers. To better
understand the development of tumors that have lost the
functions of these tumor suppressor genes, we have gener-
ated animal models by targeting these genes in the germline
of mice. Many of these mutations, when bred to homozygos-ity, however, are embryonic lethals in the mice. Conse-
quently, conditional knockouts of these genes are used to
study their functions. They include tissue-specific deletions
and inducible knockouts. Progress in these genetic manipu-
lations to study tumor development in animals with mutations
of BRCA1, DPC4, and PTEN will be described.
S-18 Drug discovery in the p53 pathway
DP Lane, C Midgley, A Sparks, C Blattner, C Binden and S Laine
CRC Laboratories, University of Dundee, Dundee, UK
The activity of the tumour suppressor protein p53 is critically
controlled by proteolysis. When cells are exposed to a variety
of stress stimuli including hypoxia, DNA damage, or the action
of certain oncogenes, this degradative pathway is inhibited
and p53 protein levels rise, inducing cell-cycle arrest and
apoptosis. The function of the p53 pathway is affected by
many DNA tumour virus-derived oncogenes. In addition, two
cellular proteins, Mdm2 and Arf, have been discovered to play
a critical role in regulating the specific stability of p53. Mdm2
binds to the N terminus of p53, recognising a specific
peptide motif, and targets p53 to the proteasome. The Mdm2
protein acts as a specific E3 ubiquitin ligase, and the Arf
protein binds to Mdm2 and inhibits its ligase activity. Recently
we have also discovered that p53 is modified by the small
ubiquitin-like protein SUMO, and this modification may inhibit
the degradation of p53. Microinjection of antibodies to the
p53-binding domain of Mdm2 will activate the p53 response
in normal cells as will mini-proteins displaying phage-opti-
mised Mdm2 binding peptides that block p53 binding. The N
terminal 64 amino acids of Arf are also a potent activator of
the p53 response, and we have recently localised the
Arf–Mdm2 interaction using pepscan libraries of Arf. An
important feedback pathway exists because the Mdm2 gene
is only transcribed in cells that contain normal p53.This
explains why tumours stain strongly with anti-p53 antibodies if
that p53 is inactive as a transcription factor. In a survey of
small molecules we found that both the nuclear export
inhibitor leptomycin B and the proteasome inhibitor Lacta-
cystin caused the accumulation of p53 in normal cells. Strik-
ingly, only Leptomycin-induced p53 was transcriptionally
active. Using inducible cell-line systems, we established that
Mdm2 targets p53 for nuclear export. The ability to induce the
p53 response with non-genotoxic agents combined with the
recognition that p53 mutant human tumours lack the Mdm2
dependant degradation pathway opens up many exciting new
approaches to drug discovery in the p53 pathway.
S-19 Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium
AF Olumi, GD Grossfeld, SW Hayward, PR Carroll, GR Cunha, P Hein and TD Tlsty
Cancer Research Center, Departments of Urology, Pathology and Anatomy, University of California at San Francisco,
San Francisco, USA
We have demonstrated that fibroblasts associated with
carcinomas stimulate tumor progression of initiated non-
tumorigenic epithelial cells both in an in vivo tissue recom-
bination system and in an in vitro co-culture system.
Human carcinoma-associated fibroblasts grown with initi-
ated human epithelial cells dramatically stimulate growth
and alter histology of epithelial cells. This effect is not
detected when normal fibroblasts are grown with the same
epithelial cells under the same experimental conditions.
From these data and other data we conclude that, in this
human cancer model, carcinoma-associated fibroblasts
stimulate tumor progression of an initiated epithelial cell.
S-20 p53-mediated apoptosis and genomic instability syndromes
EA Spillare, XW Wang, SP Linke, A Robles and CC Harris
Laboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda, MD, USA
The eukaryote genome is constantly facing the threat of
damage from exogenous and endogenous mutagens.
Mammalian cells, therefore, have evolved an intricate
network of defenses to maintain genomic stability, eg, cell-
cycle checkpoints, DNA repair, and apoptosis. Defects in
these processes can result in a mutator phenotype associ-
ated with tumorigenesis, as exemplified by a number of
familial cancer-prone disorders, including xeroderma pig-
mentosum (XP), Bloom syndrome (BS), ataxia telangiecta-
sia (AT), Werner syndrome (WS) and Li-Fraumeni
syndrome (LFS). p53 is at the crossroads of these path-
ways, and provides a biological basis for p53 being a
prime target of somatic mutations in human cancers. We
are investigating the molecular mechanisms related to
these pathways. For example, p53 binds to the basal tran-
scription and nucleotide-excision repair complex, TFIIH,
through interaction with two DNA helicases, XPB and
XPD, and cells with p53 inactivation have a reduced DNA
repair activity. Using a genetic approach, we also showed
that XPB and XPD contribute to p53-mediated apoptosis.
These data indicate that p53 may modulate either DNA
repair or apoptosis by binding to and regulating the activ-
ity of the TFIIH-associated DNA helicases. We are also
investigating the physical and functional interactions
between p53 and other DNA helicases, including WRN
and BLM. Our data are consistent with the hypothesis that
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WRN and BLM contribute to the removal of blocks in DNA
replication due to either errors during DNA metabolism or
carcinogen-induced DNA damage. WS or BS fibroblasts
have an attenuated p53-mediated apoptotic response,
and this deficiency can be rescued by the expression of
wild-type WRN or BLM, respectively. These data further
support the hypothesis that p53 can induce apoptosis
through the modulation of specific DExH-containing DNA
helicases, and may have implications for the cancer pre-
disposition observed in these genomic instability diseases.
S-21 Lessons from TP53 mutations in breast cancers: from carcinogen fingerprints to clinical correlates
P Hainaut and M Olivier
International Agency for Research on Cancer, Lyon, France
About 1000 mutations in breast cancers are listed in the
IARC TP53 mutation database [1]. Overall, the mutation
prevalence is relatively low (20–30%). Mutations are asso-
ciated with most aggressive tumor types and carry a sig-
nificant risk of bad prognosis and outcome in both
node-positive and node-negative tumors. Among tumors
expressing mutant p53, those with mutations in the L2/L3
loops of the protein (DNA-binding surface) have a poorer
response to some forms of treatment than tumors with
mutations at other sites [2]. It is noteworthy that p53
protein levels are elevated in more than 50% of breast
cancers, suggesting that p53 function may be deregu-
lated by mechanisms other than mutation.
The pattern of TP53 mutations shows a relatively high
prevalence of insertions, deletions and nonsense mutations
(altogether, 25%). The most frequent mutation type is GC
to AT transitions (40%), equally affecting CpG and non-
CpG sites. Cohort comparisons have shown differences in
the nature, localization and frequency of mutations, but
these studies need to be substantiated on larger groups [3].
Breast cancer frequently arises in Li-Fraumeni families [4].
The mutations found in this context may be considered as
representative of spontaneous mutations arising in breast
cancer. Comparison with sporadic cancer shows that two
transversions, G to T and G to C, are not found in Li-Frau-
meni breast cancer patients. These transversions repre-
sent 18% of somatic breast-cancer mutations. They show
a strong strand bias and occur at sites often mutated in
lung cancers from smokers (codons 157, 248, 249 and
273) or in bladder cancers from smokers and/or dye-
exposed workers (codons 158 and 280). Overall, these
data indicate that although most of breast cancer muta-
tions probably have a spontaneous origin, a small propor-
tion of mutations show signatures that suggest the
involvement of exogenous carcinogens.
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S-22 p53 action in apoptosis and senescence
SW Lowe, CA Schmitt, G Ferbeyre, AW Lin, E de Stanchina and M Soengas
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA
Our laboratory is interested in the genes that control apop-
tosis and cellular senescence, two conceptually related
processes that can act to limit cellular proliferation. Both
processes are frequently disrupted in cancer cells, implying
that each can limit tumor development. Moreover, since
radiation and many chemotherapeutic agents can activate
apoptosis or senescence, the integrity of these anti-prolifer-
ative programs may influence the outcome of cancer
therapy in patients. The p53 tumor suppressor can promote
apoptosis or senescence and, together with its cell-cycle
checkpoint function, acts at in a variety of ways to protect
against cancer. For example, p53 can be activated by DNA
damage to activate cell-cycle checkpoints or apoptosis,
such that cells lacking p53 are prone to certain forms of
mutation and genomic instability. This implies that p53 can
indirectly suppress tumorigenesis by acting as a ‘Guardian
of the Genome’, that is, to promote the repair or elimination
of cells sustaining potentially deleterious mutations.
Remarkably, since most current anticancer agents directly
or indirectly damage DNA, the integrity of this p53 response
may contribute to tumor cell death during therapy. In addi-
tion, certain mitogenic oncogenes activate p53 to promote
apoptosis or senescence. Loss of p53 prevents these
responses, leading to oncogenic transformation or tumor
progression. In these settings, p53 can directly suppress
tumorigenesis by acting in a fail-safe mechanism to counter
hyperproliferative signals. We are currently studying many
aspects of p53, including how oncogenes or DNA-damag-
ing agents activate p53, how p53 executes a biological
response, and how cellular factors influence whether p53
induces a cell-cycle checkpoint, cellular senescence, or
apoptosis. We are also developing animal models to
examine the impact of the p53 pathway on tumor cell
responses to anticancer agents.S-23 Cancer susceptibility in ATM heterozygotes: do two distinct carrier populations exist?
RA Gatti* and P Concannon†
*UCLA School of Medicine, Department of Pathology, Los Angeles, CA, †Virginia Mason Research Center, Seattle, WA, USA
The failure to find an increased frequency of ATM muta-
tions in large cancer cohorts, especially breast cancer, is
contrary to what was anticipated based on the increased
cancer susceptibility of obligate ATM heterozygotes from
families with ataxia telangiectasia. This apparent contra-
diction might be resolved if two types of ATM heterozy-
gotes were to exist and their phenotypes were to differ,
ie, those with truncating types of mutations (ATMtrunc)
that make no protein, and those with missense types of
mutations (ATMmis) that make reduced amounts of defec-
tive protein; the latter could create a dominant negative
effect that could be more detrimental than having no
protein at all. The phenotype of ATMtrunc/trunc mutations is
the AT syndrome; the phenotype of ATMmis/mis mutations,
judging from the few homozygous patients that have been
documented, appears to include some neurological fea-
tures and cancer susceptibility but not the typical AT syn-
drome. Evidence will be presented which suggests that
ATMmis/wt mutations are technically more difficult to
detect than ATMtrunc/wtmutations. Despite this, most large
cancer cohort studies have identified mainly missense
mutations and few truncating mutations. If substantiated,
this model would require a paradigm shift for cancer risk
analyses that would recognize the existence of different
allelic frequencies for the missense and truncating ATM
heterozygotes.
S-24 Role of the ATM gene in radiation sensitivity, relevance to breast cancer treatment
J Hall*, S Angèle*, M Vuillaume*, J-P Gérard† and P Romestaing†
*International Agency for Research on Cancer, Lyon, †Service de Radiothérapie-Oncologie, Centre Hospitalier Lyon Sud,
Pierre Bénite, France
Clinical observations of normal tissue damage are
observed in a subset of patients following radiotherapy,
with several studies reporting that up to 10% of breast
cancer patients show early or late tissue reactions. Muta-
tions in the Ataxia telangiectasia gene (ATM) result in
extreme radiation sensitivity: homozygotes are predisposed
to developing cancers at a young age and show an acute
radiation reaction when treated with conventional radiother-
apeutic doses for cancer. Heterozygotes have an
increased cancer risk, in particular breast cancer, and
some degree of sensitivity to ionising radiation (IR) has
been reported in in vitro studies. To evaluate the potential
role of the ATM gene in breast cancer development and
the radiosensitivity seen in certain breast cancer cases, we
have established lymphoblastoid cell lines (LCL) from
radiosensitive (EORTC >3) and non-radiosensitive breast
cancer patients. In some of the LCLs established from radi-
ation sensitive breast cancer patients, the level of cell sur-
vival and the p53 induction after IR exposure are lower than
those observed in control cell lines, indicative of an alter-
ation in the ATM signalling pathway. No ATM mutations
were detected in the LCLs from the 10 non-radiosensitive
breast cancer patients, whereas one truncating mutation
and 3 nucleotide changes were found in 4 out of 27 LCLs
from the radiosensitive patients. The frequency of these
nucleotide alterations in the general population is being
established, in order to determine whether they represent
cancer and/or radiation sensitivity predisposing mutations.
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S-25 Tumour-selective transcriptional targeting for breast cancer gene therapy
HC Hurst
Imperial Cancer Research Fund Molecular Oncology Unit, ICSM at Hammersmith Hospital, London W12 0NN, UK
One of the most attractive ways of targeting gene
therapy is by exploitation of the transcriptional regula-
tory elements of genes which display tissue- or tumour-
selective patterns of expression. In our Unit we have
focused on identifying the key regulatory elements in a
small number of genes known to be overexpressed in
breast tumours. Shortly, however, the power of expres-
sion profiling by chip technology will expand the range
of candidate genes enormously. This will also allow
much more specific expression-targeting constructs to
be developed by ‘mixing and matching’ elements from
different genes.
Genetic prodrug activation therapy (GPAT) depends on the
conditional expression of a gene encoding an enzyme
capable of converting a non-toxic prodrug into an active
cytotoxic agent. We have developed prototype systems
based on the proximal promoter of the human ERBB2 onco-
gene driving a variety of suicide genes in plasmid, retroviral
and adenoviral vectors. We have completed a phase 1 clini-
cal trial of direct intratumoral injection of an ERBB2-cytosine
deaminase plasmid in patients with advanced breast cancer,
and the system is about to be applied to other tumour types.
Tissue-selective targeting has also been explored using the
promoter and enhancer elements of the MUC1 gene, char-
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acteristically expressed by simple ductal epithelial cells
including those of the breast and pancreas. Combination
of the MUC1 and ERBB2 elements has proved effective
in generating constructs with dual specificity targeting.
In addition, the range of suicide genes which can be
delivered with such targeting devices can be expanded
by the use of high capacity adenoviral vectors, which
allow combinations of suicide genes to be expressed
and thus increase therapeutic effect without loss of
selectivity.
S-26 G1/S control and its deregulation in cancer
J Bartek, C Lukas, C Sørensen, E Santoni-Rugiu, J Bartkova and J Lukas
Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
Cancer is increasingly viewed as a cell-cycle disease, a
notion supported by recent accumulation of data on the
molecular basis of the cell-cycle machinery and its defects
commonly found in human tumours including breast carci-
nomas. Strikingly, the cell-cycle phase targeted most fre-
quently in multistep oncogenesis is the control of G1/S
transition. This period includes the late-G1 commitment to
replicate the genome and complete the cycle (the restric-
tion point control), and the initiation of DNA replication,
events regulated by the so-called ‘RB pathway’. While the
key components of the RB pathway qualify as proto-onco-
genes or tumour suppressors, and their aberrations may
provide direct proliferative advantage to cancer cells,
defects in the so-called checkpoint mechanisms that
monitor and help ensure the error-free execution of the
cell-cycle transitions act more indirectly, yet affect both
tumour progression and response to anti-cancer therapy.
Examples of both the oncogenic defects in the G1/S-con-
trolling machinery, and the ways proto-oncogenic events
may activate checkpoint responses, will be presented. In
addition, evidence in favour of the existence of a parallel
pathway, independent of and cooperating with the classi-
cal p16-cyclin D/CDK-pRB-E2F axis (the RB pathway) to
govern timely S-phase entry, will be reported. Finally, the
proposed candidacy of the RB pathway for the molecular
mechanism underlying the late-G1 restriction point switch
will be critically considered, and emerging data on novel
functions of the RB pathway in coordination of the cell
cycle events from late G1 until mitosis will be summarized.
These new discoveries have significant implications for
our understanding of the mammalian cell-cycle control and
its subversion in tumour cells, with emerging applications
in tumour diagnosis, prognosis, and attempts to device
new strategies to treat cancer.
S-27 Molecular control of apoptosis in the breast
C Streuli, A Gilmore, A Metcalfe, Y-J Lee, J Oliver and A Valentijn
School of Biological Sciences, University of Manchester, Manchester, UK
Understanding the molecular control of apoptosis in
breast epithelium represents an exciting new challenge in
breast biology. As a prerequisite for unravelling potential
mechanisms for apoptotic defects in neoplasia of the
breast, we have opted to decipher its regulation in normal
mammary epithelium. Apoptosis occurs naturally at several
stages of breast development; during the formation of
intraductal lumina, at the end of each menstrual/oestrus
cycle, and during involution that follows lactation. In the
latter case, experimental manipulation of nursing can result
in massive and synchronised epithelial cell apoptosis.
Moreover, the culture of primary breast epithelial explants
can be manipulated to allow synchronous apoptosis. We
have used these experimental systems to define both
extracellular regulators of survival and the intracellular
components of the Bcl-2 family that are involved with
apoptotic decisions in mammary epithelium.
It is well known that soluble factors are essential for cell
survival, and both EGF and insulin act to suppress apopto-
sis in mammary epithelium. It has also become clear that
adherent epithelial cells require interactions with the extra-
cellular matrix for their survival. Indeed, interplay between
these two types of extracellular survival factor occurs at
the level of intracellular signal transduction. We shall show
that the specialised ECM known as basement membrane
controls the ability of insulin to deliver PI 3-kinase-regu-
lated survival signals, and that this is mediated through the
integrin class of receptors.
Commitment to mammary apoptosis in vivo is regulated
through a wide spectrum of Bcl-2 family proteins, including
Bcl-x, Bcl-w, Bax, Bak, and Bad. Part of the control of apop-
tosis comes from the developmental regulation of gene
expression in this family, since transcription of Bcl-w, Bak
and Bad is altered as cells enter post-lactational involution.
In addition, cell-autonomous regulation of apoptosis in the
absence of protein synthesis is also a key player, and the
cell death protein Bax regulates apoptosis through its sub-
cellular localisation. In healthy cells Bax is cytoplasmic, but
altered survival signalling promotes translocation to mito-
chondria: we now know that the ECM has a critical role in
regulating Bax distribution, and that this occurs through
protein tyrosine kinase signal-transduction pathways.S-28 Hypoxia and tumour angiogenesis involved in breast cancer progression and targets for therapy
AL Harris
ICRF Medical Oncology Unit, Churchill Hospital, Oxford, OX3 7LJ, UK
Tumours cannot grow above 1–2 mm in diameter without
developing a new blood supply. We, and others, have
shown that the number of blood vessels in breast cancer is
related to prognosis, and that multiple growth-factor path-
ways control angiogenesis. One of the most important
ones is vascular endothelial growth factor and thymidine
phosphorylase. Both are targets of therapy, and currently
there are trials running inhibiting VEGF signalling pathway
and also using prodrugs activated by thymidine phosphory-
lase to produce cytotoxic agents. Hypoxia is a major factor
switching on angiogenesis, and new approaches using the
hypoxia signalling pathways to activate gene therapy in
breast cancer have been initiated. Hypoxia activates vascu-
lar endothelial growth factor production by the transcription
factor hypoxia inducible factor 1a (hif1), which binds to
specific DNA sequences. Using DNA constructs with mul-
timers of these response elements has generated reagents
that will specifically switch on under hypoxia and activate
prodrugs. Since tumours are much more hypoxic than
normal tissues, this should provide marked differential
expression. Also, these areas of tumours are resistant to
radiotherapy, so it will be particularly useful in worse prog-
nosis resistant tumours. We raised antibodies to hif1, and
to another member of the family, hif2.
Staining breast tumours showed marked induction of hif2
expression in stromal macrophages, whereas hif1 was
expressed in the epithelium around the areas of necrosis.
Thus, there are two different hypoxia-regulated pathways
activated. We have also screened for novel genes induced
by hypoxia, and found that another transcription-factor
pathway downstream of hif as well as enzymes regulating
pH are modified. These are new potential targets for
therapy.
S-29 Telomerase: a breast cancer chemopreventive and therapeutic target
JW Shay
The University of Texas Southwestern Medical Center, Dallas, Texas, USA
Telomeres are repetitive DNA sequences at the end of
linear chromosomes. Each time a cell divides some telom-
eric sequences are lost. When telomeres are short, cells
enter an irreversible growth arrest state called replicative
senescence. In most instances cells become senescent
before they can become a cancer cell. However, almost all
cancer cells are immortal, having overcome cellular senes-
cence. Maintenance of telomere stability is required for
cells to escape from replicative senescence and proliferate
indefinitely. Telomerase, a cellular reverse transcriptase, is
upregulated or reactivated in most cancers and helps to
stabilize telomere length by adding TTAGGG repeats onto
the telomeres. The correlation between telomerase activity
and human tumors suggests that tumor growth requires
reactivation of telomerase and that telomerase inhibitors
represent a novel class of chemotherapeutic agents.
Human cancer cells treated with oligonucleotide-based
antisense chemistries (peptide nucleic acid or 2¢-O-
meRNA), directed against the template region of telom-
erase RNA, inhibit telomerase activity inside cells at phar-
macological dosages. Telomerase inhibition leads to pro-
gressive telomere shortening, causing immortal human
breast epithelial cells to undergo apoptosis. Telomerase is
also being considered as a target for molecular chemopre-
ventive strategies to inhibit immortalization. Expressing a
dominant-negative mutant of the telomerase catalytic
subunit prevents the spontaneous immortalization of TP53-
heterozygous Li-Fraumeni Syndrome-derived breast epithe-
lial cells. These results not only validate telomerase as a
target for breast cancer prevention and therapy, but also
supply insights into the properties that successful anti-
telomerase agents will require. To confirm action through a
telomerase-dependent mechanism, inhibitors but not
chemically-related molecules should (i) reduce telomerase
activity but not initially affect cell growth rates; (ii) lead to
progressive shortening of telomeres with each cell division;
and (iii) cause cells to die or undergo growth arrest in a
time frame dependent on initial telomere length.
S-30 Blood assays for earlier detection of cancers
AB Pardee, RJ Guan, HL Ford, MV Fournier, K Martin and R Sager
Dana-Farber Cancer Institute, Boston, MA, USA
A significant way to improve therapy against cancer is to
detect cancer earlier than we can at present. Current
methods are similar to trying to put out a fire after the
house is in flames. Rather, we need to invent ‘smoke
detector’ techniques that signal very early cancer or the
development of metastases. These would allow treatment
of far fewer cancer cells, prior to extensive metastases
and drug resistance. They should aid present treatments
by surgery, radiation, chemotherapy and perhaps immunol-
ogy and differentiation therapy.
http://breast-cancer-research.com/supplements/2/S1Breast Cancer Research    Vol 2 Suppl 1 The Second International Symposium on the Molecular Biology of Breast Cancer
Our goal is to devise early warning systems. We already
have found many mRNAs whose expression is modified in
cancers (Sager, 1997; Ford, 1998; Fournier, 1999a, b;
Guan, 2000; Martin, 2000). We are now developing
markers and methods to detect very low numbers of tumor
cells that are released into blood early in the progression
of solid tumors. Some of these markers are found in 3 ml
blood samples from cancer patients, and are missing from
blood of normal individuals.
To find new genes we apply the concept of Expression
Genetics (Sager, 1997), using the differential display
method (Pardee, 1999). We are analysing 200 differen-
tially expressed mRNAs from breast cancers, applying
high density membrane-based hybridization arrays.
Cluster analysis identifies groups of genes whose
expression patterns correlate with clinical information,
including estrogen receptor status, tumor size, and stage
(Martin, 2000). The early detection methods we are
developing could also be applied to predict optimal
cancer therapy, to determine therapeutic efficacy by
measuring decreases of markers in blood, and to detect
recurrence after therapy. These techniques could be
applied to other body fluids.
S-31 Abstract not submitted for publication
S-32 Predictive factors in breast cancer
J Klijn, E Berns, L Dorssers and J Foekens
Dr Daniel den Hoed Cancer Center/Academic Hospital Rotterdam, The Netherlands
In the processes of malignant transformation, tumor cell
growth regulation, angiogenesis and metastasis, and the
development of drug resistance, a large number of onco-
genes, suppressor genes, proteases and their inhibitors
are involved. In addition to the classical clinical prognostic
factors, many of these molecular biological parameters are
increasingly used as prognosticator and predictive factors
for response to therapy, and recently also as targets for
new biologic therapeutic strategies.
In nearly 2800 patients with primary breast cancer and in
830 patients with recurrent disease we investigated by uni-
variate and multivariate analysis the prognostic and/or pre-
dictive value of a large series of more than 20 molecular
biological factors. In patients with primary breast cancer c-
myc amplification, TP53 mutation and increased expression
of cathepsins and/or components of the urokinase-type plas-
minogen (UPA) activator system showed clear prognostic
value. The most powerful predictive factors for a favorable
response to endocrine therapy are ER, PgR, and PS2, while
HER2-neu, EGF-R, TP53 mutation and expression, uPA and
TK are associated with a poor response to tamoxifen. Mainly
TP53 mutations, TS and MRP expression were associated
with type of response to chemotherapy. Germ-line mutations
in the breast cancer genes 1 and 2 (BRCA1/2) were associ-
ated with a similar prognosis as observed in patients with
sporadic breast tumors in spite of different tumor character-
istics (Verhoog et al, Lancet 1998 and J Clin Oncol 1999).
Recently a new gene associated with tamoxifen resistance,
located at human chromosome 16q, was detected in over
97 patients. High Bcra1/p130Cas protein levels were asso-
ciated with poor prognosis (ES van der Flier et al, J Natl
Cancer Inst 2000, 92:120–127).
In conclusion, an increasing number of cell biological
factors such as HER2-neu appear to be of clinical impor-
tance because of their predictive value and their role as
(potential) targets for therapy.
While adjuvant chemotherapy as well as hormone therapy
improve long-term survival in breast cancer patients [1,2],
only about 25–30% of patients at risk are cured by such
treatment modalities. While improved regimens using more
effective chemotherapeutics have been shown to improve
outcome marginally [3], the disappointing results from high-
dose chemotherapy with stem cell support [4,5] underlines
the limitations associated with current chemotherapy.
While expression of the estrogen and progesterone
receptors have been used to select patients for endocrine
treatment, so far we have lacked predictive factors with
respect to outcome in chemotherapy. Over the last
decade, laboratory investigations have revealed several
potential mechanisms explaining resistance to chemother-
apy. Thus, there is evidence that loss of function of the
TP53 gene may confer resistance to chemotherapeutics
like the anthracyclines but does not deteriorate response
to the taxanes [6,7], a finding supported by recent studies
in breast cancer patients [8,9].
These findings may challenge the way we are running clin-
ical trials in breast cancer patients. If certain gene muta-
tions predict for resistance to specific drugs, the key
target for future studies should be to outline these mecha-
nisms  in vivo. While combined therapy regimens may
S-33 Clinical trials in breast cancer; do we have the right approaches?
PE Lønning
Section of Oncology, Department of Medicine, Haukeland University Hospital, Bergen, Norwayimprove response rates to some extent, such approaches
would imply over-treatment with increased toxicity in many
patients who would not benefit from one or more of the
drugs in the ‘cocktail’. It may even be detrimental to clini-
cal outcome as it may require reduction in the dose of
active drugs. Retrospective evaluation of predictive factors
in adjuvant studies are complicated by several confound-
ing factors like inappropriate tissue sampling (paraffin-
embedded only), use of combined regimens and inferior
surrogate markers for therapeutic efficacy (time to relapse
versus direct antitumour effects). Evaluation of predictive
factors should preferably be done in relation to monother-
apy with single chemotherapeutics in the advanced or
neoadjuvant setting, and such results are likely to have a
strong influence on how we design adjuvant studies in the
future.
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S-34 Tissue microarrays for high-throughput profiling in molecular oncology
O-P Kallioniemi, J Kononen and G Sauter
Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20852, USA
and Institute of Pathology, University of Basel, Switzerland
High-throughput genome screening technologies, such as
CGH, cDNA microarrays, SAGE, differential display, and
DNA sequencing have made it possible to survey thou-
sands of genes per tumor. The translation of such informa-
tion to improved diagnostic, prognostic and therapeutic
applications in the clinic requires extensive data ‘mining’
as well as validation, prioritization and extension of such
results to hundreds or thousands of clinical specimens.
This is often extremely tedious with conventional molecular
pathology technologies. We have developed a novel tech-
nology, tissue microarrays (‘tissue chips’) for facilitating
such ‘genome-scale’ translational cancer research [1].
This technology enables high-throughput molecular analy-
ses of hundreds of tissue specimens or cells in a single
experiment. Tissue microarrays are constructed by acquir-
ing cylindrical biopsies from 500–1000 individual tumor
tissues into a tissue microarray block, which is then sliced
to over 200 sections for probing DNA, RNA or protein
targets. A single immunostaining or in situ hybridization
reaction now provides information on all of the specimens
on the slide, while subsequent sections can be analysed
with other probes or antibodies. Construction of multiple
replicate blocks may allow up to 100000 sections to be
generated from the same series of tumor specimens. This
expands the scope of microarray technologies to the
rapid, very large-scale molecular analysis of thousands of
tissue specimens with thousands of probes for various
DNA, RNA and protein targets. For example, we have uti-
lized the combination of cDNA and tissue microarray tech-
nologies to uncover genes involved in breast and prostate
cancer progression. In summary, tissue microarrays
provide a powerful approach for the in vivo validation of
gene discoveries, as well as a means to rapidly assess the
clinical significance of molecular alterations.
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S-35 Two molecular cytogenetic views of breast cancer
J Gray*, K Chin*, C Collins*, P Yaswin†, G Nonet†, D Kowbel*, W-L Kuo*, E Garcia†, C Ortiz de Solorzano†, D Knowles†,
S Lockett†, M Bissell†, V Weaver†, D Pinkel*, D Albertson*, A-L Børresen-Dale‡ and F Waldnian*
*UCSF Cancer Center, University of California, San Francisco; †Biomedical Sciences Division, Lawrence Berkeley National
Laboratory, Berkeley, CA, USA and ‡Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway
This talk will present two views of genome evolution in
human breast cancers using fluorescence in situ hybridiza-
tion (FISH) and comparative genomic hybridization
(CGH). FISH with chromosome-specific probes applied to
thick tissue sections from tumors at several stages of pro-
gression reveals a remarkable level of cell-to-cell variability
beginning with hyperplasia and increasing with increasing
grade. These studies also demonstrate significant
genomic evolution, including formation of polyploid nuclei
within a single sample, suggesting a very high rate of
genomic instability. These phenomena also were observed
in vitro in few-cell clones established from breast cancer
cell lines. Paradoxically, CGH analyses of ‘average’
genome copy number changes show relatively slow
overall rates of evolution in vitro and in vivo. CGH kary-
otypes for breast cancer cell lines change relatively slowly
as long as the environment remains constant. Likewise,
CGH karyotypes of pairs of primary vs. metastatic or in
situ vs. invasive breast tumors from the same patient are
usually quite similar, suggesting a relatively slow rate of
evolution. Possible explanations for this paradox will be
discussed.
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Higher resolution analyses of selected regions of recurrent
genomic abnormality on chromosome 20, using array
CGH and FISH, suggest the coordinate amplification of
several genes that play a role in breast cancer evolution.
Complete sequencing of a ~1 Mb wide region centered
on a region of recurrent amplification at 20q13.2 has
revealed several genes that appear as possible candidate
‘driver’ genes including ZNF217, a gene now implicated in
the immortalization of breast epithelial cells.
S-36 Studying breast cancer on a genomic scale using DNA microarrays
D Botstein and PO Brown
Stanford University School of Medicine, Stanford, California, USA
Genome-wide studies of human gene expression have
become possible in recent years because of the availabil-
ity of most of the sequences of protein-encoding genes.
Technology has been developed in our group to obtain
and analyze patterns of expression of many thousands of
genes at once. We have begun to apply cDNA microarray
technology to the study of cancer, focusing on breast
cancer. We characterized the variation in patterns of gene
expression in a set of 62 surgical specimens of human
breast tumors from 40 different patients, using cDNA
microarrays representing 8102 different human genes.
The observed gene expression patterns provided a
remarkably distinctive molecular portrait of each tumor.
Twenty of the tumors had been sampled twice, both
before and after a 16-week course of doxorubicin
chemotherapy, and two tumors were paired with a lymph
node metastasis from the same patient. The gene expres-
sion patterns observed in the serial samples from the
same tumor, and the tumor/metastasis pairs, were almost
always more similar to each other than either was to any
other samples. Clusters of co-expressed genes were iden-
tified, for which variation in mRNA levels could be related
to specific features of physiological variation, or to varia-
tion in the cellular constituents of the tumors. The tumors
could be classified into subtypes that were distinguished
by pervasive differences in their gene expression patterns.
Such classifications were robust, and reflected changes in
gene expression in the epithelial cells as well as differ-
ences in expression derived from the populations of non-
epithelial cells in the tumors. These results suggest that
gene expression patterns can provide distinctive and rec-
ognizable molecular portraits of individual tumors, and
perhaps a basis for a new molecular classification of
cancers.PI-01 Denaturing high-performance liquid chromatography (DHPLC) as a fast tool to screen a control
population for the occurrence of unclassified variants (UV) in the BRCA1 gene
N Arnold, E Gross, H Peper, K Bandick, W Jonat and M Kiechle
Department of Gynecology and Obstetrics, Michaelisstr. 16, 24105 Kiel, Germany
The identification of BRCA1 and BRCA2 mutations has
enabled physicians to identify persons at high risk for carci-
noma of the breast and ovary in hereditary breast-ovarian
cancer (HBOC) families. Tests for known mutations are very
sensitive and specific. The interpretation of previously unde-
scribed variants (UV) is complicated because it could be
either a cancer-causing mutation or a polymorphism. Until a
functional test is available, general population frequency
analysis of unclassified variants in the BRCA1 coding region
is useful to support the putative role of missense mutations.
In contrast to the very cumbersome evaluation of sequence
data, the evaluation of results by DHPLC is quite effortless
because the investigator has to discriminate only between
single and multiple peaks in the elution profiles. The following
reported UVs were analysed with the DHPLC technique:
A835G; C1605T; G2531C; A2577G; C2596A; C2640T;
C2715T; G3238A; G4654T; T5002C; C5029T; G5075A
and 5136 del CAC. The analysis was done with DNA from
98 persons (81 females and 17 males) who had no BRCA1
related carcinomas in their family history. The ages for the
females range from 58 to 92 years (median 73 years) and for
the males from 58 to 87 years (median 70 years). With this
strategy we detected G5075A four times, G3238A two
times and C2715T one time. Therefore, these BRCA1 alter-
ations can be considered as rare polymorphisms. The other
investigated UVs could not be detected in the samples and
the nature of the alterations still remains unclear. With the
DHPLC technique we also detected two novel alterations
G1606A and G1736A. Sequence comparison with dog
BRCA1 reveals that G1606A represents a wild-type consti-
tution and G1736A is a silent mutation. Therefore both alter-
ations represent rare polymorphisms.
PI-02 Clinical and pathological characteristics in patients with BRCA1/2-mutation associated with
breast cancer (BC) with a long clinical follow-up
O Díez*, C Pericay†, M Domènech*, J Brunet†, J Cortés*, J Balmaña†, A Gómez‡, JJ López†, MC Alonso† and M Baiget*
*Serveis de Genètica, †Oncologia Mèdica y ‡Radiodiagnòstic, Hospital de Sant Pau, Barcelona, Spain.
It is not known if the behaviour of hereditary breast cancer
(HBC) differs from that of sporadic BC. We analysed
clinico-pathological characteristics in 17 patients with
BRCA1/2 germline mutations associated with BC. These
data could be useful in the management of HBC. All
patients except 4 had a family history of BC or ovarian
cancer (OC). Mutation detection methods were SSCP
and PTT (exon 11 for BRCA1, exons 10 and 11 for
BRCA2) and final direct sequencing. The BRCA1 muta-
tions found were: exon 2 185delAG, exon 2 189insTGTC,
exon 5 330A-G, exon 11 1241delAC, exon 18 5263G-A,
exon 23 5537delA, and exon 24 5625G-T. The mutations
in  BRCA2 were: exon 11 3374delA, 6076del4bp,
6857delAA, and exon 23 9254del5bp. At diagnosis the
mean age was 37 years (28–53). Only 3/17 patients pre-
sented with involvement of axillary nodes; no patient was
diagnosed with metastatic disease. All cases presented
infiltrating ductal carcinoma; two of them were medullar
carcinoma. Histological grade was available in 13/17
cases, with grade III being the most frequent (12/13). Hor-
monal receptors were negative in 8/10 patients. The mean
follow-up is 129 months (24–224). There were three local
recurrences at 17, 108 and 151 months; and two distant
relapses at 15 months (complete remission) and at 92
months. Three contralateral BC were diagnosed. HBC has
malignant pathological features, but the clinical behaviour
seems not to be more aggressive than the sporadic BC in
the same age group.
PI-03 A novel BRCA2 gene mutation, 4081 insA, in a Finnish breast/ovarian cancer family associated
with favourable clinical course
J Hartikainen*, V Kataja† and A Mannermaa*
*Chromosome and DNA Laboratory, Bldg 2 C, PO Box 1777, FIN-70211 Kuopio, †Department of Oncology, Kuopio University
Hospital, Finland
Annually more than 3000 new breast and 400 ovarian
cancer cases are diagnosed in Finland. It is estimated that
inherited predisposing genes will cause 150–320 cases of
breast and 20–40 cases of ovarian cancer each year. In
Poster presentations
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Finland 18 different BRCA1/2 mutations have been found.
Eleven of these mutations are recurrent (including four
founder mutations unique to Finland) and one of 18 is
unique to one family (4081insA). We have studied 38
Eastern Finnish breast/ovarian cancer families for BRCA1
and BRCA2 germline mutations. The 4081insA mutation
was detected in PTT analysis and it was confirmed by het-
eroduplex, sequencing and haplotype analysis. The inser-
tion of an adenine causes frameshift, which leads to a
translation terminating signal and protein truncation at
codon 1288. The 4081insA mutation is in the BRCA2
gene ovarian cancer cluster region (OCCR) in exon 11.
We screened a family of the index patient, her three broth-
ers and four sisters. Mutation was found in three sisters
and one brother, in addition to the index patient and one of
her three sons. The 4081insA mutation is rare and has a
high penetrance; four of six mutation carriers in the family
are affected with breast (two cases) or ovarian cancer (two
cases). There were no other cancer cases in the family.
Two mutation carriers, both males, at the age of 76 and 59
years, are so far apparently healthy with no symptoms. The
four sisters each had an advanced type of breast or ovarian
cancer with a poor prognosis. However, they all had a
good response to treatment and after 9 to 19 years follow-
up time no recurrence has been seen and all are alive and
well. Although the mutation is highly penetrant, the breast
and ovarian cancer patients carrying it, in this family, seem
to have an exceptionally good clinical course.
PI-04 Breast cancer in young women: prevalence of LOH at p53, BRCA1 and BRCA2
SM Johnson, JA Shaw and RA Walker
Breast Cancer Research Unit, University of Leicester, Clinical Sciences, Glenfield Hospital, Groby Road, Leicester, LE3 9QP
Previous studies have shown that breast cancers show
more aggressive pathological features in younger women
than those occurring in older women. These findings have
raised the question whether differences are present at the
molecular level. In order to examine genetic alterations
associated with early onset breast cancer 31 cases,
selected for age under 35 at diagnosis, were examined for
loss of heterozygosity (LOH) and microsatellite instability
(MI) in three key chromosomal intervals: 17p13 (p53),
17q11–22 (BRCA1) and 13q12–14 (BRCA2). The
cases selected had no obvious family history. DNA was
extracted from formalin-fixed paraffin embedded normal
and tumour tissue (whole section and microdissected
DNA) and analysed by PCR amplification of microsatellite
repeat markers. Products were resolved on 10% non-
denaturing polyacrylamide gels and silver stained.
28/31 (90%) cases exhibited LOH for at least one marker
and 19 (61%) cases showed LOH at 2 or more markers.
There was no MI detected. The frequency of LOH detected
for each of the markers was as follows: 17p, D17S796
(37%) and D17S799 (61%); 17q, D17S855 (65%) and
THRA1 (41%); and 13q, D13S171 (48%). These frequen-
cies are higher (apart from THRA1) than those previously
reported for unselected series of breast cancer. Other
markers are currently being investigated. These results
suggest that LOH at these regions could be related to
early onset breast cancer and to poor tumour prognosis.
PI-05 BRCA1 mutation analysis in breast and ovarian cancer families from Greece
I Konstantopoulou*, C Croupis†, A Ladopoulou*, A Pantazidis*, E Lianidou†, K Venetsanou‡, E Efstathiou‡, M Petersen¶,
J Janinis‡††, G Fountzilas§††, E Chiotellis* and D Yannoukakos*
*Molecular Diagnostics Lab, I/R-RP, National Center for Scientific Research ‘Demokritos’ Athens, †Laboratory of Analytical
Chemistry, Department of Chemistry, University of Athens, ‡Agii Anargyri Cancer Hospital, Athens, ¶Department of Genetics,
Institute of Child Health Athens, §AHEPA Hospital, Aristotle University of Thessaloniki Medical School, ††Hellenic Cooperative
Oncology Group, Athens, Greece
We have been constructing a genomic DNA database
from breast/ovarian cancer patients with a family history, in
collaboration with several Greek hospitals. The criteria
used for the selection of high-risk families are those
accepted universally. In the present study we report three
frameshift mutations in BRCA1. These mutations were
found in female patients with a family history of
breast/ovarian cancer, and are all located in exon 11.
Mutation identification was made using PTT and direct
sequencing. The first mutation identified is 3741insA
(codon 1208), carried by a woman who developed bilat-
eral breast cancer at age 31 with her mother’s sister
affected with breast cancer at age 35. This mutation is
reported only once in the BIC database. The second case
is a woman with ovarian cancer carrying the mutation
1623del5-TTAAA (codon 502). Her daughter developed
breast cancer and her mother endometrial cancer. This
mutation has been reported 6 times in the BIC database.
The third BRCA1 mutation, 3099delT (codon 994) is a
novel mutation and was found in a woman with ovarian
cancer at age 33, with her sister and mother affected with
ovarian cancer at different ages. Her grandmother was
also affected with breast and ovarian cancer. We have
also screened breast/ovarian patients with a family history
for two mutations with strong founder effects, 22 patients
for 185delAG and 26 patients for 5382insC. None of
these mutations was found, indicating that their frequency
in Greece might be quite different from those reported byOlah  et al [1] concerning Central and Eastern Europe.
Mutation analysis of more breast/ovarian patients is in
progress. This is the first report of BRCA1 deleterious
mutations identified in Greece.
Reference
1. E. Olah et al: Abstract book, A22. BCLC meeting, Nov 28–Dec 1,
1999.
PI-06 BRCA1, BRCA2 and pedigree genetic analysis to determine genetic risk in the UK Royal Marsden
Hospital tamoxifen prevention trial
Z Kote-Jarai*, TP Powles†, S Ashley†, DF Easton‡, L Assersohn†, N Sodha†, M Dowsett*, B Gusterson*, A Tidy†, G Mitchell*†
and RA Eeles*†
*Institute of Cancer Research, Sutton, Surrey, SM2 5NG, †Royal Marsden NHS Trust, Sutton, Surrey, SM2 5PT, ‡CRC Genetic
Epidemiology Unit, Strangeways Research Laboratories, Cambridge, CN1 4RN, UK
In the Royal Marsden Hospital tamoxifen prevention study,
2500 women at increased risk of developing breast
cancer because of family history of the disease were ran-
domised to receive tamoxifen 20 mg daily or placebo for 8
years. 70 woman developed primary breast cancer; 36
whilst on placebo, 34 on tamoxifen. Family history out to at
least 2nd degree relatives was taken from all women in the
study. DNA from peripheral blood from 67 of the 70
women was analysed for coding mutations in the BRCA1
and BRCA2 genes by CSGE analysis of the entire coding
region of both genes. 7 mutations were found, 2 in
BRCA1 and 5 in BRCA2; 4 would be expected to be
pathogenic as these were nonsense/frameshifts. 3 were
rare variants which were not present in 100 normal con-
trols. The posterior probability of carrying a breast cancer
predisposition gene in the individuals who developed
breast cancer was assessed using the Cyrillic genetic risk
package, based on the Claus model. 26 women had
<50% posterior probability of harbouring a breast cancer
predisposition gene and 44 had a ³50% chance of having
a breast cancer predisposition gene. In the former group
of 26 women, 8 had been taking tamoxifen and 18
placebo. In the group of women with ³50% probability of
having a breast cancer gene, 26 had been taking tamox-
ifen and 18 placebo. The differences between the
numbers of women taking tamoxifen who subsequently
developed cancer in the two groups divided by <50% or
³50% genetic risk was significant (P = 0.04). These pre-
liminary data suggest that tamoxifen prevention may be
more effective in women with a <50% chance of harbour-
ing a breast cancer predisposition gene. A meta analysis
of the interaction of genetic status with tamoxifen chemo-
prevention effectiveness should be conducted to test this
hypothesis.
PI-07 Mutational analysis of BRCA1 and BRCA2 genes in Spanish women with early-onset breast
cancer
JI Martínez-Ferrandis*, A Vega‡, P Marín-Garcia*, F Barros‡, FJ Chaves*, A Carracedo‡, ME Armengod*, I Chirivella†,
A Lluch†, J García-Conde† and A Cervantes†
*Instituto de Investigaciones Citológicas, 46010 FVIB, Valencia, †Hospital Clínico Universitario, 46010 Valencia, ‡Unidad de
Medicina Molecular, Hospital de Conxo, Santiago de Compostela, Spain
Germ line mutations in the BRCA1 and BRCA2 genes pre-
dispose women to breast cancer. The prevalence of BRCA1
and BRCA2 mutations in patients with breast cancer who
were unselected for a family history has not been determined
in the Mediterranean area. We have screened for BRCA1
and BRCA2 mutations 110 women diagnosed with breast
cancer before age 40 years in order to determine the preva-
lence of these mutations. This screening was performed by
using PCR-SSCP analysis of multiplexes and DNA frag-
ments resulting from digestion of about 1300 bp-long PCR
products with restriction endonucleases. Sequencing of
abnormal bands was used to identify mutations.
Mutations that are predicted to encode truncated protein
were detected in 7 (6.3%) of 110 women with early onset
breast cancer (2 BRCA1 and 5 BRCA2). Mutations that
encode missense amino acid change were detected in 8
(7.2%) (4 BRCA1 and 4 BRCA2). This information is
important because it determines the cost-benefit implica-
tions of genetic testing. We predict that BRCA1 and
BRCA2 mutations are approximately equal in our popula-
tion. A low proportion of the early-onset breast cancer is
attributable to mutations in these genes. Clinical and his-
tological features of these women carrying BRCA1\
BRCA2 mutations will be presented.
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PI-08 One test to identify 50% of all Norwegian BRCA1 mutations
P Møller*, E Hovig*, K Lycke*, RAP Stacy†, OJ Dahlberg†, A Hagen‡, B Hagen‡, K Løvslett¶, H Qvist* and K Heimdal*
*The Norwegian Radium Hospital, N-0310 Oslo, †GenoVision AS, Gjerdrumsvei 12a, 0486 Oslo, ‡Regional University Hospital,
N-7600 Trondheim, ¶Central Hospital, N-4000 Stavanger, Norway
In Norway, 1675delA, 1135insA and 816delGT together
account for more than half of all BRCA1 mutations in
breast-ovarian cancer kindreds (Disease Markers 1999,
15:79–84). We have set up a system for determining
absence/presence of these three mutations. DNA is iso-
lated from frozen, whole blood using the GenoPrep instru-
ment for automated nucleic acid purification. The
automated system is based on the use of magnetic
microparticles, giving high quality DNA for PCR-reactions.
The instrument can process 48 samples at a time. The
system is designed to handle 100 ml blood per sample
and produces quantities of DNA sufficient for at least 100
PCR reactions (approximately 3 mg). A multiplex PCR-
based fragment analysis has been established employing
30 PCR cycles on a GeneAmp System 7600 cycler
(PE-AB). The resulting three fragments are subjected to
gel electrophoresis after denaturation by means of the Alf
Express™ (Pharmacia Biotech) for 160 min, and all frag-
ments scored for size variations due to insertions/dele-
tions. The normal product sizes for the three amplified
fragments are 85 bp (816delA), 140 bp (1135insA) and
63 bp (1675delA), respectively. Probable mutants are ver-
ified by sequencing.
Norwegian health authorities have confirmed that the treat-
ing physician may obtain informed consent and obtain blood
for mutation analysis; the patient is referred to genetic coun-
selling when a mutation is demonstrated. The activity will
define patients and families with mutations for health care, it
is cost effective (Disease Markers 1999, 15:167–173), and
we may obtain population-based estimates of prevalences,
penetrances and expressions of the mutations.
PI-09 Germline TP53 mutations in Finnish breast cancer patients
K Rapakko*, M Allinen*, K Syrjäkoski†, P Vahteristo‡, P Huusko*, K Vähäkangas¶, H Eerola§, T Kainu†, O-P Kallioniemi†, 
H Nevanlinna‡ and R Winqvist*
Departments of *Clinical Genetics, and ¶Pharmacology and Toxicology, University of Oulu/Oulu University Hospital, Oulu,
†Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University Hospital, Tampere, Departments of
‡Obstetrics and Gynecology, and §Oncology, Helsinki University Central Hospital, Helsinki, Finland
Breast cancer is the most frequent malignancy among
women, positive family history being one of the strongest
risk factors. Mutations in BRCA1 and BRCA2 account for
a portion of inherited predisposition to breast cancer, but
recently it was discovered that mutations in these two
genes were less common in the studied Finnish cancer
families than expected. Therefore, mutations in other sus-
ceptibility genes have actively been searched for. TP53 is a
tumor suppressor gene that is often found mutated in the
Li-Fraumeni syndrome (LFS). Germline alterations of TP53
are also thought to cause predisposition to breast cancer.
In a previous study by Huusko et al [1], we screened
Finnish LFS families for TP53 exon 5–8 mutations and
detected two, Tyr220Cys (exon 6) and Asn235Ser (exon
7), both of which appeared to be associated with accumu-
lation of female breast cancer cases in particular.
We have now screened 130 BRCA1 and BRCA2 nega-
tive breast cancer patients from 104 families for germline
TP53 mutations covering the whole protein-encoding
region of the gene. Our criteria for inclusion were: three or
more cases of breast cancer in first- or second-degree rel-
atives, early onset of the disease (<35 years), bilateral
breast cancer, or multiple tumors including breast cancer
in the same individual. The screen for mutations was per-
formed using conformation sensitive gel electrophoresis
(CSGE) or fluorescence-CSGE (F-CSGE). One missense
mutation (Arg248Gln in exon 7) was identified in a family
with multiple cases of breast cancer, one of which was
bilateral, at very young age of onset. All three Finnish
TP53 germline mutations have previously been observed
in LFS and breast cancer patients with bilateral tumors or
young age of onset. To characterize further the nature of
the identified mutations, control DNAs from 500 unse-
lected consecutive breast cancer cases were studied. No
additional mutations were found, supporting the notion
that these TP53 germline alterations are disease-related.
These mutations were also searched for in additional
breast cancer families originating from the same geo-
graphical regions as those with mutations, but there was
no evidence of founder effects that otherwise are common
in hereditary diseases in Finland. Our results indicate that
the breast cancer-related germline TP53 mutations mainly
occur at specific mutation-prone regions of conserved
regions of the gene (exons 6-7), and explain a small addi-
tional fraction of the BRCA1 and BRCA2-negative breast
cancer cases.
K Rapakko and M Allinen made an equal contribution to this work.
Reference
1. Huusko P et al: Cancer Genet Cytogenet 1999l, 112:9–14.PI-10 X chromosome inactivation pattern in female patients with breast cancer
M Kristiansen*, A Langerød†, GP Knudsen*, BL Weber‡, A-L Børresen-Dale† and KH Ørstavik*
*Department of Medical Genetics, Ullevål University Hospital, Oslo, †Department of Genetics, Norwegian Radium Hospital, Oslo,
Norway, ‡Cancer Centre, University of Pennsylvania, Philadelphia, USA
In females one of the two X chromosomes is inactivated in
early embryonic life, thus making females mosaics for two
cell lines. Most females have a 50:50 distribution of the
two cell lines. A deviation from this distribution is called a
skewed X inactivation. Skewed X inactivation may be a
result of a chance event, due to genetic factors or a selec-
tion mechanism. Older females have an increased fre-
quency of skewed X inactivation in peripheral blood cells.
An association between skewed X inactivation and
BRCA1 mutation in germline DNA of patients with ovarian
cancer was recently reported (Buller et al 1999). A signifi-
cant increase in skewed X inactivation pattern was also
found in patients with invasive cancer compared to
patients with borderline cancer and healthy controls, indi-
cating that skewed X inactivation is a predisposing factor
for the development of invasive ovarian cancer.
We have analysed X inactivation pattern in peripheral
blood from 216 female patients with breast cancer and 26
cancer patients with documented BRCA1 germline muta-
tion. Controls were female blood donors. X-inactivation
was classified as skewed when 90% or more of the periph-
eral blood cells preferentially used one X-chromosome.
Among females with documented BRCA1 germline muta-
tion, 15% had a skewed X inactivation compared to 8% of
female patients without BRCA1 mutation (P = 0.20) and
1% of control females (P = 0.008). Females who devel-
oped breast cancer at young ages (25–45 years) had a
significantly higher frequency of skewed X inactivation
than control females of the same age group (P = 0.009).
A germline mutation in an X chromosome tumour suppres-
sor gene could give a proliferative advantage to cells with
this mutation on the active X chromosome, thus causing
skewed X inactivation.
PI-11 HRAS1 minisatellite alleles and breast cancer in Spanish women under age forty years
A Vega*, JI Martínez†, F Barros*, P Marín-García†, FJ Chavez†, C Ruiz-Ponte*, I Chirivella‡, A Lluch‡, A Cervantes‡,
I García-Conde‡, ME Armengod† and A Carracedo*
*Unidad de Medicina Molecular, Hospital de Conxo, Santiago de Compostela, †Instituto de Investigaciones Citológicas 46010,
FVIB, Valencia, ‡Hospital Clínico Universitario, 46010, Valencia, Spain
Some rare genetic variants in a variable tandemly repeated
region (minisatellite) of the H-ras gene have been associ-
ated with increased risk of cancers, including breast
cancer. The aim of this work is to examine the possibility
that rare alleles of HRAS1 minisatellite are implicated in
the predisposition to develop early-onset breast cancer.
Methods: One hundred and nine blood samples of a
control population from healthy donors, and 95 samples
from unrelated women under 40 years old at diagnosis of
a first primary breast cancer, have been studied for
HRAS1 minisatellite locus. The analysis of HRAS1 alleles
was performed using fluorescent detection of size alleles
and MVR-PCR.
Results: After the analysis of the HRAS1 MVR sequences
and the length polymorphism typing in the healthy control
population and the affected patients, we have observed that
20% of breast cancer patients had at least one rare HRAS1
allele compared to 6.42% of HRAS1 alleles in the control
population (c2, P = 0.0037). Therefore, the risk of develop-
ing breast cancer increases with the presence of rare alleles
(OR = 3.64 and 95% CI = 1.46–9.09). Only 11.58% of
breast cancer patients studied showed HRAS1 intermedi-
ate alleles, an important decrease compared with 25.69%
of intermediate alleles found in the control population.
Conclusions: Our results suggest that the frequency of
rare HRAS1 alleles is increased in early-onset breast
cancer women, in comparison with a control population.
There is also an important decrease in intermediate alleles
in the breast cancer population.
PI-12 Germline BRCA2 and somatic P53 alterations in male breast cancer
B Csokay, N Udvarhelyi and E Olah
National Institute of Oncology, Department of Molecular Biology, Budapest, Hungary
Cancer of the male breast is infrequent, accounting for
less than 1% of all breast cancer cases in the Western
world. Hungary is leading in the mortality rate for this
disease in continental Europe. In our recent report [1] a
high frequency (33%) of germline BRCA2 mutations was
detected among Hungarian male breast cancer cases
without family history. In the current study our aim was to
extend these preliminary data on BRCA2 germline alter-
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ations and determine additional somatic genetic changes
in both BRCA2 carrier and non-carrier male breast
cancers. P53 expression was studied in samples of 32
male breast cancer patients by immunohistochemical
analysis using DO-7 and BP-53 antibodies. Unexpectedly,
no sample showed overexpression of the P53 protein by
either of the antibodies used in our series. To determine
whether lack of overexpression was due to absence of
mutations in p53, we carried out mutation analysis of the
gene using SSCP and direct sequencing of the variants.
Updated results of this analysis will be presented.
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PI-13 Constitutional alterations of 9p23-24 in independent BRCA2 breast cancer families
M Schwab, L Savelyeva, A Claas, H An and S Brouwers
Division of Cytogenetics, German Cancer Research Center, 60120 Heidelberg, Germany
Germ line mutations of BRCA2 are predicted to account for
the majority of families with both male and female breast
cancer. However, there is circumstantial evidence that the
cancer risk conferred by BRCA2 mutation may be modified
by other genetic or environmental factors. By employing a
combination of classical G-banding and fluorescence in situ
hybridization analyses we have identified chromosomal
alterations on 9p23–24 in peripheral lymphocytes of inde-
pendent BRCA2 breast cancer patients. Tandem duplica-
tion and amplification with inversion are constitutional
rearrangements in four male breast cancer patients from
two high-risk families. Interstitial deletion of the same region
was found in four male and one female patients from an
independent family. The biological significance of the coex-
istence of BRCA2 mutation and 9p23–24 abnormalities in
breast cancer families may be complex. Possible explana-
tions include (1) the BRCA2 mutation is related to the 9p-
rearrangement, or (2) the 9p rearrangement is elicited by
another as yet unknown factor, and chromosomal changes
on 9p could be related to modifying cancer risk.
PI-14 kConFab: a unique Australasian research initiative for familial breast cancer
J Sambrook
Peter MacCallum Cancer Institute, Melbourne, Australia
The Kathleen Cuningham Foundation Consortium for
Research into Familial Aspects of Breast Cancer
(kConFab) is a unique Australasian research co-operative
which brings together geneticists, clinicians, surgeons, sci-
entists, pathologists, psychologists, oncologists and epi-
demiologists from 32 institutions in New Zealand and the
five mainland States of Australia. The aims of the Consor-
tium are to identify Australasian families with predisposition
to breast/ovarian cancer through Familial Cancer Clinics in
Australia and New Zealand, to identify the predisposing
genes and characterise germline mutations. The study aims
to determine the effect of the type of mutation and the influ-
ence of lifestyle and environmental factors on the type, age
of onset and severity of cancer, the response of the
patients to treatment and the psychosocial consequences.
In addition to genetic, epidemiological and medical data,
kConFab obtains and stores clinical samples, DNA, RNA,
tumour and prophylactically removed tissue. All data are
stored in a relational database that is accessible for
approved basic and clinical research projects.
As of January 2000, kConFab has identified over 700
Australasian families, who have presented at Family
Cancer Clinics with exceptionally severe histories of
breast or breast/ovarian cancer and features suggesting a
dominantly-inherited predisposition to the disease. To
date, over 2200 individuals have consented to donate
blood and complete questionnaires concerning their
health, diet and lifestyle. By the end of the accrual phase
of the study (2002), kConFab expects to have accumu-
lated genetic and epidemiological information on at least
7000 members of high-risk families, including first and
second degree relatives of all mutation carriers and indi-
viduals affected with breast or ovarian cancer. Further
information about kConFab may be found on our website
at http://www.pmci.unimelb.edu.au/kconfab.
Acknowledgement: On behalf of the Kathleen Cuningham Foundation
Consortium for Research into Familial Breast Cancer (kConFab).
PI-15 Germline mutations of BRCA1-associated RING domain (BARD1) gene in breast and/or ovarian
families negative for BRCA1 and 2 alterations
C Ghimenti*, E Sensi*, D Iandolo*, G Cipollini*, S Ricci†, PF Conte†, G Bevilacqua* and MA Caligo* 
Department of Oncology, *Division of Pathology and †Division of Medical Oncology, University of Pisa, Italy
BARD1 (BRCA1-associated RING domain) has been
identified by yeast two-hybrid screening as a protein
specifically interacting with the product of BRCA1 gene.
Somatic and germline mutations of BARD1 have beendetected in sporadic breast, ovarian and endometrial
cancers. In this study, we evaluate the frequency of
BARD1 germline mutations in 20 Italian hereditary breast
and breast-ovarian families tested negative for BRCA1
and BRCA2 mutations. Two families were breast-ovarian,
11 had more than four cases of breast cancer and five had
only two affected in the family. Mutational analysis was
performed by SSCP for the entire coding region and exon-
intron splice boundaries of BARD1 gene. Direct sequence
analysis was used to identify the genetic alterations. We
found three different germline alterations of the BARD1
gene, two missense and one frameshift: a G>C transver-
sion in codon 557 that produces an aminoacidic change
Cys>Ser in exon 7; a A>G transition in codon 295 that
produces an aminoacidic change Asn>Ser in exon 4; a
21 bp deletion after nucleotide 1071 that produces an in-
frame deletion of 7 aminoacid in exon 4.
A group of 20 sporadic breast cancers below 40 years of
age, selected as a control group was analyzed. We found
only a somatic mutation in one tumor.
The mutation was the same in-frame deletion found in the
family group. A study of loss of heterozigosity of BARD1
locus (D2S143, D2S164 and D2S295 markers) in the
tumor tissues of patients carrying the BARD1 mutations is
under investigation.
These data suggest that BARD1 could be involved in the
susceptibility of hereditary breast and ovarian tumors.
This work was supported by AIRC.
PI-16 Mammary-specific targeting of the murine BRCA2 breast cancer susceptibility gene in mice
NK Collins, KA McAllister, LM Bennett, K-U Wagner, T Ward, J Malphurs, G Goulding, EM Eddy, BJ Davis and RW Wiseman
National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC 27709 and NIDDK, NIH, Bethesda, MD
20892, USA
Women with inherited mutations in the BRCA2 gene have
a very high lifetime risk of developing breast cancer. Previ-
ously, we used gene targeting with embryonic stem cells
to generate mice with a mutation that disrupts exons 10
and 11 of the Brca2 gene. Mice that are homozygous for
this mutation exhibit an embryonic lethal phenotype. To
overcome this difficulty we have generated mice with loxP
sites flanking Brca2 exon 27. Prior studies have shown
this C-terminal domain of Brca2 interacts with Rad51, and
cells that lack Brca2 exon 27 are hypersensitive to
gamma-radiation. Therefore, site-specific recombination of
loxP sites and deletion of exon 27 in this floxed Brca2
allele by a Cre recombinase should disrupt basic functions
of  Brca2  in DNA repair. The mammary-gland-specific
removal of Brca2 exon 27 by Cre-mediated recombination
in vivo has been accomplished by crossing the homozy-
gous floxed Brca2 mice with a mouse mammary tumor
virus (MMTV)-Cre strain D transgenic mice. Analyses of
ROSA26 LacZ Cre reporter mice confirm that this MMTV-
Cre transgene is specifically activated at the onset of
puberty in mammary epithelial cells. In parallel studies a
germline deletion of exon 27 was created by transiently
electroporating embryonic stem cells carrying the floxed
Brca2 allele with a Cre-expression plasmid. Surprisingly,
mice homozygous for the germline deletion of exon 27
appear to be completely viable at birth, but preliminary
studies suggest impaired male fertility. Gross phenotypic
abnormalities in mammary gland ductal morphogenesis
have not been shown by mammary whole mount prepara-
tions in these animals at up to six months of age. These
mice are being observed closely for neoplastic develop-
ment in mammary glands as well as other tissues.
Mammary-specific Brca2D27 mice should be a valuable
experimental model mimicking the breast tumor develop-
ment of women who have inherited a BRCA2 defect and
then acquire a secondary somatic BRCA2 mutation.
PII-01 Relative expression of progesterone receptors A and B in premalignant and invasive breast lesions
P Mote and C Clarke
Westmead Institute for Cancer Research, University of Sydney, Westmead, NSW 2145, Australia
Progesterone is critical in mammary gland development.
Breast cancer evolves from normal tissue through increas-
ingly abnormal cellular changes that include increased
expression of progesterone receptor (PR), and PR is an
established marker of response to endocrine therapy. PR is
expressed as two proteins (PRA and PRB) with different
functions, and in vitro evidence reveals PRA to inhibit PRB
function. This suggests that PRA may repress progesterone
action and that the ratio of PRA:PRB may be an important
determinant in tissue sensitivity to ovarian steroid hormones.
This study examined the expression of PRA and PRB proteins
in normal breast tissue (n=13) during the menstrual cycle,
and in premalignant (n=45) and malignant (n=39) breast
tissues, to determine differences in relative isoform expres-
sion. We used dual immunofluorescent histochemistry on for-
malin-fixed, paraffin-embedded tissue sections using mouse
monoclonal antibodies that bind to either PRB or PRA.
In most normal breast cases PR staining was confined to
scattered epithelial cells expressing equivalent levels of
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PII-04 Genetic variants of CYP19 (aromatase) and breast cancer risk
V Nedelcheva Kristensen*, N Harada†, N Yoshimura†, E Haraldsen*, PE Lønning¶, B Erikstein‡, R Kåresen§, T Kristensen††
and A-L Børresen-Dale*
*Department of Genetics, ‡Department of Oncology, Institute of Cancer Research, The Norwegian Radium Hospital, Montebello
0310, Oslo, Norway, †Department of Biochemistry, School of Medicine, Fujita Health University, Toyoake, Japan, ¶Department of
Oncology, Haukeland Hospital, University of Bergen, §Department of Oncology, Ulleval Hospital, Oslo, ††Department of
Biochemistry, University of Oslo, Norway
The effect of an SNP in exon 10 of CYP19 on tumour
mRNA levels and splice variants was studied and corre-
lated with clinical parameters and risk of breast cancer. In
the vast majority of breast cancers, the estrogen levels
PII-02 Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human
breast epithelial cell lines involve different pathways
BK Lundholt, P Briand and AE Lykkesfeldt
Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, DK-2100
Copenhagen Ø, Denmark
Epidermal growth factor (EGF) and estradiol (E2) are impor-
tant mitogens in breast epithelial cells, and expression of
epidermal growth factor receptor (EGFR) and estrogen
receptor (ER) is often inversely correlated in human breast
cancer cells. Stable transfection of ER-negative cells with
ER cDNA is not sufficient to restore E2-mediated growth
stimulation, suggesting a disturbance of this inverse correla-
tion in ER-transfected cell lines. In this study we used the
ER-transfected human breast epithelial cell lines HMT-
3522F9, growth inhibited by E2 in the presence of EGF,
and HMT-3522F9/S3B, growth stimulated by E2 in the
absence of EGF. The E2-mediated growth regulatory differ-
ences of the cell lines were not due to altered expression of
EGFR, TGFa, or c-erbB2 mRNA. A decreased MAP kinase
activity was observed in HMT-3522F9 cells in response to
E2, indicating that in these cells altered cross-talk between
the ER and the EGFR/MAP kinase signalling pathway could
be due to the E2-stimulated growth inhibition. Interestingly,
no changes in EGFR, ErbB2 or MAP kinase activity was
observed in E2-stimulated in HMT-3522F9/S3B cells in
response to E2, suggesting a MAP kinase-independent E2-
mediated growth stimulatory mechanism. We are currently
investigating the pathway(s) involved in the E2-mediated
growth stimulation of HMT-3522F9/S3B cells.
PII-03 Hairy and enhancer of split homolog-1 (HES-1) mediates the proliferative effect of 17b b-estradiol
on breast cancer cell lines
A Ström, N Arai, J Leers and J-Å Gustafsson
Karolinska Institutet, Department of Biosciences at Novum, S-141 57 Huddinge, Sweden
The mechanism behind estradiol-dependent growth of
breast cancer is presently not well understood. We show
that the hairy and enhancer of split homolog-1 (HES-1)
protein level in the breast cancer cell lines T47D and
MCF-7 is down-regulated by 17b-estradiol treatment. This
regulation could be reversed by addition of the anti-estro-
gens 4OH tamoxifen, raloxifen and Imperial Chemical
Industries (ICI) 182,780. Furthermore, T47D cells with
inducible exogenous HES-1 expression showed that HES-
1 protein needs to be removed in order for 17b-estradiol
to have a proliferative effect and subsequently up-regulat-
ing proliferating cell nuclear antigen (PCNA).
An inverse correlation between the protein levels of
HES-1 and PCNA was found in colon cancer cell lines.
These findings point to a role of HES-1 as a tumor sup-
pressor in epithelial cells, and as a target for 17b-estra-
diol in breast cancer cells. Present findings makes
HES-1 useful for diagnosis and an interesting target for
cancer treatment.
PRA and PRB. However, 50% of cases in the luteal phase
(n = 6) showed reduced PRA expression. In proliferative
premalignant lesions without atypia (PDWA, n = 15), there
was a marked increase in intensity and number of cells
expressing PR, but inter-cell homogeneity was maintained.
Atypical proliferative benign lesions (ADH, n = 15; DCIS,
n = 15), showed high levels of both PRA and PRB expres-
sion with notable inter-cell heterogeneity in relative isoform
content. This was also observed in malignant breast
tumours (n = 39). Furthermore, breast tumours expressing
an overall predominance of one isoform were associated
with features of higher histological grade.
In conclusion, our results show a change from inter-cell
homogeneity of PRA:PRB in normal tissue to extensive
heterogeneity in the malignant state, suggesting a pro-
gressive loss of control of relative PRA and B expres-
sion that may occur early in cancer development and
may eventually be associated with features of poorer
prognosis.PII-05 The involvement of the MAPK signalling pathway in the adaptation of MCF-7 cells to long-term
oestrogen deprivation
L-A Martin, CMW Chan, C Marshall and M Dowsett
Institute of Cancer Research, Fulham Road, London, UK
The molecular mechanism associated with the transition of
breast tumours to steroid hormone-independent growth is
poorly understood. However, a number of studies have
demonstrated the potential role of the mitogen-activated
protein kinase (MAPK) signalling pathway in the initiation
and pathogenesis of breast cancer.
In an attempt to study the transition to oestrogen-indepen-
dent growth, wild-type (wt) MCF-7 cells were cultured in
oestrogen (E2)-deficient medium for over 100 weeks.
During this time the cells were characterised and shown
to pass through three distinct phases. Quiescent (LTED-
Q), followed by an increase in basal growth rate paralleled
by hypersensitivity to E2 (LTED-H), and finally transition to
an E2-independent phase (LTED-I). Western blot analysis
of the LTED cells showed elevated levels of ERa com-
pared to the wt MCF-7 cells. The ERa was phosphory-
lated on serine 118 despite absence of E2.
Assessment of the level of activated MAPK showed a
mean 7-fold increase in LTED-Q, 4- fold in LTED-H and 6-
fold in LTED-I compared to the wt MCF-7 cells. As the
LTED-I phase progressed MAPK levels fell, but after 90
weeks remained 30% higher compared to wt MCF-7.
Suppression of MAPK activity in LTED-I cells, using a
MEK inhibitor, significantly reduced but did not block ERa
phosphorylation. Similarly transfection of LTED-I cells with
an E2 responsive reporter construct (pEREtkCAT), fol-
lowed by treatment of the cells with a MEK inhibitor,
resulted in a 50% decrease in basal ERa transcription.
However, a combination of E2 and the MEK inhibitor sup-
pressed ERa-directed transcription by only 30% com-
pared to E2 alone.
These data support previous findings that elevated MAPK
levels are found during ligand-independent cell prolifera-
tion. However, this is unlikely to be the sole pathway
operating to achieve this adaptation; rather a complex
network of kinases and molecular switches may operate
at different temporal stages during long-term oestrogen
deprivation.
PII-06 Phosphorylation of human progesterone receptors by MAPKs mediates transcriptional synergy
between progestins and MEKK1 in human breast cancer cells
CA Lange*, T Shen† and KB Horwitz†
*University of Minnesota Cancer Center, Minneapolis, MN, and †Division of Endocrinology, University of Colorado Health
Sciences Center, Denver, CO, USA
Breast cancers that are steroid-hormone resistant often
overexpress growth factor receptor tyrosine kinases,
including members of the type I (EGFR/Erb2) family.
Cross-talk between growth factor- and progesterone-
mediated signal transduction pathways may contribute to
the development of resistance to steroid hormone-based
therapies in breast cancer. To mimic constitutive activation
of molecules downstream of growth factor signalling path-
ways, we overexpressed activated MAP/ERK Kinase
Kinase (MEKK) in T47D human breast cancer cells. MEKK
is a strong activator of p42/p44, and p38 mitogen acti-
vated protein kinases (MAPKs). MEKK expression resulted
in 20-fold increased R5020-mediated transcription driven
by a co-expressed progesterone-response-element (PRE)-
containing promoter linked to the luciferase reporter gene;
progesterone receptor (PR) levels did not change in the
presence of MEKK alone, but decreased in the presence
of MEKK and R5020. Potentiation by MEKK of progestin-
induced transcription also occurred in HeLa cells, and
was dependent on the presence of a PRE, and functional
PR. PR antagonists RU486 and ZK98299 blocked this
effect. The MEK inhibitor, PD98059, also blocked tran-
scriptional synergy between MEKK and progestins, indi-
cating a requirement for p42 and p44 MAPKs. To test
modulate the tumour growth and depend on the activity
of  CYP19. Patients (n = 481) and controls (n = 236)
were genotyped by T-tracks in a single sequencing reac-
tion (SSR). The frequency of TT genotypes was signifi-
cantly higher in patients versus controls (P = 0.007)
particularly among those with stage III and IV disease
(P = 0.004) and with tumours larger than 5 cm
(P = 0.001). A significant association between presence
of the T allele and the level of aromatase mRNA in the
tumours was observed (P = 0.018), as well as with a
switch from adipose promoter to ovary promoter
(P = 0.004). Previously, we reported a rare polymorphic
allele of CYP19 (repeat (TTTA)12) to be significantly more
frequent in breast cancer patients than in controls. Here
we describe another polymorphism, a C-T substitution in
exon 10 of the CYP19 gene which is in strong linkage
disequilibrium with the (TTTA)n polymorphism but with
higher frequency of the variant allele. Our data suggest
that the T-allele of the CYP19 gene is associated with a
‘high activity’ phenotype.
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whether the effect of MAPK activation was due to direct
phosphorylation of PR, we expressed MEKK in T47D cells
stably expressing either wild-type or mutant PR, in which
either of two MAPK consensus site serine residues, Ser
294 or Ser 345, were mutated to alanine. Both MAPK
mutants of PR were resistant to MEKK- and R5020-
induced transcriptional synergy, but, like wild-type PR, still
responded to progestins alone. Thus, mutant PR are func-
tional in response to progestins, but are incapable of
cross-talk with MAPK-driven pathways. Phosphorylation of
PR by MAPKs in response to peptide growth factor sig-
nalling may increase PR transcriptional activity on PRE-
containing growth regulatory genes, thus altering steroidal
control of breast cancer cell growth.
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PIII-01 The expression of the EGFR family members in breast carcinomas
Z Suo and JM Nesland
Department of Pathology, The Norwegian Radium Hospital and Institute for Cancer Research, University of Oslo, Norway
The EGF receptor family members (EGFR, c-erbB-2, c-
erbB-3 and c-erbB-4) of tyrosine kinase receptors are
involved in the regulation of cell growth and differentiation.
Differential expression of such members in breast carcino-
mas may be associated with different clinical behaviours.
A series of Norwegian and Chinese breast cancer patients
has been examined in our laboratory with the same
immunohistochemical protocol. The expression rate of
EGFR, c-erbB-2 and c-erbB-3 in these two series was
similar, 43.9%, 37% and 22% in the Norwegian series
and 53%, 35.8% and 17% in the Chinese series, respec-
tively. Comparing the immunohistochemical results in
available benign breast material and ‘normal’ material in
breast carcinomas, we conclude that the expression of
EGFR, c-erbB-2 and c-erbB-3 is increased in breast
malignancy. The expression rate of c-erbB-4 was lower in
the Chinese series, 45.7% vs 81%. That was probably
due to the fact that there were more grade III tumours in
the Chinese series, since the expression of c-erbB-4 was
found to be inversely associated with histological grade in
invasive ductal carcinomas. Compared with the expression
in benign and normal breast tissues, the expression of c-
erbB-4 was, however, decreased in breast carcinomas in
both series. Available follow-up data in the Chinese series
demonstrated that c-erbB-4 expression in node-negative
breast carcinomas was associated with better prognosis,
but not c-erbB-4 expression in node-positive carcinomas.
It is concluded that while the expression of EGFR, c-erbB-
2 and c-erbB-3 is associated with cancer development,
the expression of c-erbB-4 may have a different role.
PIII-02 IGFBP-7 expression in human breast cancer and association with proliferation and cell cycle
aberrations
H Östlund*, A Burger†, A Seth‡ and G Landberg*
*Department of Medical Biosciences, Pathology, Umeå University, Sweden, †Tumor Biology Center at the University of Freiburg,
Germany, ‡Department of Laboratory Medicine and Pathobiology, University of Toronto, Women’s College Hospital, Toronto,
Canada
The complex insulin-like growth factor network of ligands,
receptors and binding proteins has been shown to be dis-
turbed in breast cancer, potentially leading to IGF1 recep-
tor activation and uncontrolled tyrosine kinase signalling.
In addition to defects in proteins controlling cell cycle
checkpoints, this type of aberrations could affect tumor
growth and survival, thereby influencing both tumor
aggressiveness and potential response to treatments. We
have earlier shown that the T1A12/mac25 protein, which
is identical to the insulin-like binding protein (IGFBP-7), is
differentially expressed in breast cancer cells compared
with normal cells. The gene product seemed to be lost in
the progression from premalignancy to invasive breast
cancer and loss of heterozygosity (LOH) of the 4q12–13
region was frequently observed in invasive cancers, sug-
gesting a suppressor-life function for IGFB-7. In 104 inva-
sive breast cancers arranged in a tissue-array system, all
with known status of cell-cycle aberrations and clinico-
pathological data, the expression of IGFB-7 was moni-
tored using immunohistochemistry. Cytoplasmic staining
of variable intensity was observed in the tumors and 14%
lacked IGFBP-7 staining, 20% had low staining, 32%
intermediate staining and 34% strong staining. Low IGFB-
7 was associated with high cyclin E expression,
retinoblastoma protein inactivation, low bcl-2 and poorly
differentiated tumors. There was further a significantly
impaired prognosis for patients with low IGFB-7 protein
tumors. Interestingly, IGFB-7 was strongly and inversely
associated with proliferation (Ki-67 %) in estrogen recep-
tor-negative tumors, suggesting an important cell-cycle
regulatory function for IGFBP-7 separate from the interac-
tion with the estrogen receptor pathway.PIII-04 Expression of Akt kinases related to ErbB2 and results of adjuvant therapy of breast cancer
O Stal, L Akerberg, B Nordenskjold, B Olsson, LE Rutqvist and L Skoog
Department of Oncology, University Hospital, Linkoping, Oncologic Center and Division of Cytology, Karolinska Hospital,
Stockholm, Sweden
It has been suggested in several studies of breast cancer
that overexpression of the growth factor receptor erbB2 is
associated with less benefit from certain adjuvant treatments.
The mechanisms are not fully understood. The erbB2 recep-
tor activates several signal pathways including the phos-
phatidyl-inositol-3-kinase (PI3-K)/Akt (also known as PKB)
pathway, which is implicated in cell survival. This pathway
has shown to be a target of the tumor suppressor PTEN.
We have analysed the expression of Akt1 and Akt2 by
immunohistochemistry in frozen tumor samples from 280
postmenopausal patients who participated in a randomised
trial comparing CMF chemotherapy and postoperative radio-
therapy. The patients were simultaneously randomised to
tamoxifen or no endocrine treatment. A marked cytoplasmic
staining in more than 10% of the malignant cells for Akt1
was observed in 24% of the cases. Thirty percent showed
staining for Akt2. Among Akt2-positive tumors, Akt1 was
more frequently expressed in erbB2-positive compared with
erbB2-negative cases, 62% and 30%, respectively
(P= 0.005). Akt1+/ER+ patients seemed not to benefit from
adjuvant tamoxifen (RR = 0.93, 95% CI 0.35–2.8), whereas
the Akt1-/ER+ group showed a significantly improved
distant recurrence-free survival with tamoxifen (RR = 0.51,
95% CI 0.31–0.84, P= 0.0056). No interactions were
observed between Akt1 or Akt2 and the result of CMF vs
radiotherapy treatment considering distant recurrence-free
survival. For locoregional recurrence a high expression of
either Akt1 or erbB2 or both significantly predicted a poor
benefit from radiotherapy vs CMF (P= 0.038).
PIII-05 Anti-HER2 mAb plus calicheamicin immunoconjugate linked on liposomal vinorelbine induces
ADCC and apoptosis in HER2-positive high grade DCIS
J Giannos and P Ginopulos
Department of Clinical Oncology, Regional Hospital, St. Andreas, Greece
Overexpression of the HER2 proto-oncogene which
encodes a 185 kDa protein frequently coincides with
aggressive and chemoresistant DCIS due to inhibition of
PCD after chemotherapy. Also, it is associated with aneu-
ploidy, p53 abnormalities, enhanced DNA repair and syn-
thesis, cell growth, mitotic rate and tumorigenicity. Tissue
from high-grade DCIS was excised from a patient, and
tumour cells were isolated by the collagenase method.
Analysis with IHC showed HER2 overexpression. We
prepared immunoconjugates of anti-HER2 mAbs and
calicheamicin, which is an apoptotic antibiotic with up to
1000-fold greater potency than the clinically most used
anticancer drugs. This immunoconjugate was linked onto
pegylated DRV liposomes which contained vinorelbine.
After treatment, we observed HER2 downregulation by
IHC. TEM exhibited disruption of the microtubular
cytoskeleton due to vinorelbine, and mAb(Fc)-directed
killing of tumour cells by immune effector cells such as
Development of acquired resistance against antiestrogen
treatment is a serious problem in human breast cancer,
and knowledge of alterations resulting in resistance is
important for selection of further treatment. To mimic the
clinical situation we have established a series of MCF-7
human breast cancer cell lines by long term treatment with
the antiestrogens tamoxifen, ICI 164,384, and ICI
182,780 (Faslodex™). Common for these cell lines is a
decreased expression of the estrogen receptor a (ERa).
In human breast cancer, lack of response to endocrine
therapy is often associated with decreased expression of
the estrogen receptor and increased expression of epider-
mal growth factor receptor (EGFR) and/or HER-2/neu
(ErbB-2). Our antiestrogen-resistant cell lines did not
express altered levels of EGFR, HER-2/neu, ErbB-3 and
ErbB-4. Estrogen and antiestrogen regulation of HER-
2/neu expression was essentially similar in parent and
resistant MCF-7 cells. Treatment with antibodies to HER-
2/neu (Herceptin™) did not affect growth of MCF-7 cells
or resistant cells, indicating that in this in vitro model
system, acquired antiestrogen resistance does not
emerge from activation of the HER-2/neu signalling
pathway. However, addition of heregulin1-b1 abolished
the inhibitory activity of ICI 182,780 on MCF-7 cells,
demonstrating that activation of the HER-2/neu receptor
signalling pathway can override the growth inhibitory
effect of ICI 182,780. The effect of heregulin1-b1 could
be abrogated by Herceptin™.
PIII-03 Activation of the Her2/neu receptor leads to antiestrogen resistance, but acquired resistance is
not caused by altered ErbB expression and activation
SS Larsen and AE Lykkesfeldt
Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, DK-2100
Copenhagen Ø, Denmark
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macrophages, neutrophils and lymphoid cells such as K
and NK cells, indicating antibody-dependent cellular toxi-
city (ADCC). Biochemical assays such as MTT exhibited
reduced metabolic activity, while BrdU showed great
reduction of DNA synthesis. Anti-ssDNA mAbs and
binding of Annexine-V with phosphatidyl-serine IHC con-
firmed that apoptosis was the mechanism of growth inhi-
bition. SEM and TEM showed violent membrane blebbing
of apoptotic cells (zeiosis), and fragmentation of DNA
creating a vacuolar nucleus due to calicheamicin-damag-
ing action after binding to the third end of oligopurine
tracts causing strand breaks. Subsequently, tumour cells
break up into apoptotic bodies that adjacent cells recog-
nise and phagocytose due to PS externalisation, indicat-
ing a bystander killing effect (BKE). We conclude that by
delivering intracellularly cytotoxic agents such as
calicheamicin through conjugating to antiHER2 mAbs
linked on liposomal vinorelbine, we can circumvent
chemoresistance, induce ADCC, inhibit mitosis at
metaphase and destroy tumoral DNA, leading to irre-
versible D2 apoptotic signs with subsequent bystander
killing of high grade DCIS.
PIII-06 Factors modulating integrin b bI expression on the breast cancer cell lines MCF-7 and MDA-MB-
231
CJ Pogson, CMW Chan, L-A Martin, GPH Gui and M Dowsett
Departments of Academic Surgery and Biochemistry, The Royal Marsden and Institute of Cancer Research, Fulham Road,
London, England
The metastatic cascade describes a sequence of cellular
events that forms the pathological basis of tumour pro-
gression. The integrins are cell adhesion molecules that
play a leading role in this complex process. The objective
of this study is to improve our understanding of the role of
integrins in breast cancer metastasis by investigating how
growth factors (Epidermal Growth Factor (EGF) and
Insulin-like Growth Factor 1 (IGF-1)), oestradiol (E2) and
tamoxifen affect integrin bI expression. The breast cancer
cell lines MCF-7 and MDA-MB-231 were used and inte-
grin expression measured by Western Blotting.
We have demonstrated that EGF and IGF-1 up-regulate
integrin bI expression on the MDA-MB-231 cell line by
2.7- and 2.8-fold respectively. By doing so these cells may
generally become more adhesive and therefore less prone
to metastasise. Tamoxifen down-regulated integrin bI
expression on this oestrogen receptor (ER)-negative cell
line, with maximal effect at 10–6 M (34% reduction). This
suggests signalling through an alternative pathway. Inte-
grin down-regulation may render cells less adhesive and
therefore less invasive.
High concentrations of E2 significantly up-regulated integrin
bI expression on the MCF-7 cell line, whereas low concen-
trations resulted in a down-regulation, with maximal effects
at 10–7 M (1.7-fold induction) and 10–11 M (29% reduction)
respectively. Conversely, high concentrations of tamoxifen
down-regulated integrin bI expression and low concentra-
tions up-regulated expression, with maximal effects at 10–8
M (49% reduction) and 10–9 M (2.7-fold induction) respec-
tively. These data provide a cellular basis for the modulation
of integrin expression and may explain why some ER-nega-
tive patients respond well to tamoxifen. Identification of
factors that regulate integrin expression may lead to the
development of novel anti-metastatic agents.
PIII-07 HER-2 activation and TP53 inactivation as predictors of survival in breast cancer
TI Andersen*†, E Skovlund‡, IK Bukholm†, U Jacobsen¶, R Kåresen¶, B Erikstein‡, J Nesland§ and A-L Børresen-Dale†
Departments of *Oncology and ¶Surgery, Ullevål University Hospital, N-0407 Oslo, Norway. Departments of †Genetics,
¶Oncology, and §Pathology, The Norwegian Radium Hospital, N-0310 Oslo, Norway
Activation of the HER-2 proto-oncogene and inactiva-
tion of the TP53 tumour-suppressor gene belong to the
most common genetic changes in human breast carci-
nomas. Both appear to be of prognostic significance, at
least in patients with node-positive disease. The rele-
vance of these changes in node-negative disease,
however, still remains uncertain. Moreover, the relation-
ship between HER-2 and TP53 status remains to be
fully clarified.
HER-2 and TP53 status were determined in 261 breast
carcinomas collected from Norwegian breast cancer
patients diagnosed between 1984 and 1994. HER-2
status was determined using immunohistochemistry. A
subset of the tumours was also examined with regard to
gene amplification using the Southern blot technique. A
significant association was found between the presence
of gene amplification and positive HER-2 immunostaining
in the tumour. The tumours were also examined for TP53
alterations using CDGE (constant denaturant gel elec-
trophoresis) and immunohistochemistry. A significant
association was found between the presence of HER-2
activation and TP53 inactivation in the tumour. Survival
analyses will be presented.This prospective study will include patients who are at
least 18 years of age, with a histologically or cytologically
confirmed diagnosis of advanced breast cancer (ABC),
who have failed or are resistant to treatment with at least
two chemotherapy regimens for ABC, and who overex-
press HER-2. A maximum of 62 patients are to be
included for the detection of an overall response rate of
20% (10–30%, 95% confidence interval). 
Her-2 status will be analyzed with immunohistochemistry
(Novocastra NCL CB-11, mouse monoclonal antibody).
Treatment will be single dose trastuzumab: 4 mg/kg first
treatment, and 2 mg/kg thereafter, for at least 10 cycles.
Tumor response and side effects will be documented. In a
separate protocol bone marrow micrometastasis will be
analyzed.
The study started at the end of December 1999. Four
patients have been included so far. More data and some
results will be presented at the meeting.
PIV-01 Role of the breast cancer susceptibility gene BRCA1 in radio-resistance
V Sylvain and Y-J Bignon
Laboratoire d’Oncologie Moléculaire EA 2145, Centre Jean Perrin, BP392 58 Rue Montalembert 63011 Clermont-Ferrand
Cedex1, France
Evidence that BRCA1 is involved in DNA repair stems
from its interaction with proteins like RAD51, RAD50,
etc We hypothesised that overexpression or antisense
inhibition of the mouse homologue Brca1 in an ovarian
cancer cell line could result in changes of sensitivity to g-
radiation.
Mouse ovarian cancer cell line ID-8 was transfected or
infected with Neo-resistant vector or retrovirus expressing
full-length  Brca1 in the sense or antisense orientation.
G418-resistant colonies were isolated (two sense, S2 and
S13, and three antisense, AS1, AS2 and AS3) and levels
of Brca1 were quantified by real time quantitative RT-PCR.
Cells were incubated in 96-well culture plates at 37°C for
24 hours. They were irradiated (0, 1, 3, 5 and 10 Gy),
incubated at 37°C for 24 hours, washed, and postincu-
bated at 37°C in fresh medium for 48 hours, after which
cell density was measured using a colorimetric assay with
sulforhodamine B.
Colonies S2 and S13 respectively expressed very low and
high levels of Brca1 transgene, and expression of trans-
gene in colony AS2 was 12- and 60-times higher than in
colonies AS1 and AS3 respectively. Overexpression of
Brca1 resulted in enhanced resistance to irradiation (1.2
to 1.5-fold), whereas inhibition of expression of Brca1
resulted in a very slight increase in sensitivity. Increased
radio-resistance induced by overexpression of Brca1 is
consistent with other studies, and supports a role for
BRCA1 in DNA damage repair. On the other hand, the
discrepancy between our results obtained with inhibition
expression of Brca1 and data in the literature (ionising
radiation hypersensitivity in human cancer cells containing
mutated BRCA1 and mouse embryonic stem cells carry-
ing a Brca1 null mutation) is unexpected. We need to
investigate further the inhibition of expression of protein
Brca1 and above all its functional properties, analysing
expression profiles of BRCA1 downstream target genes
like p21, GADD45, c-myc etc
PIV-02 BRCA2 interacting proteins
H Vidarsson, E Mikaelsdottir, JE Eyfjörd, H Ögmundsdóttir, T Rafnar and S Valgeirsdóttir
Laboratory for Molecular and Cell Biology, Icelandic Cancer Society, Reykjavik, Iceland
Two breast cancer susceptibility genes (BRCA1 and
BRCA2) have been cloned. A BRCA2 founder mutation,
BRCA2 999del5, accounts for the majority of familial breast
cancer cases in Iceland. Individuals heterozygous for this
mutation are at an increased risk of developing breast
cancer, but the risk varies between families, indicating vari-
able penetrance. BRCA2 encodes a protein of 3418 amino
acids with a molecular weight of 384 kDa. The biological
function of BRCA2 is, as yet, not well known, but several
studies have shown that BRCA2 interacts with proteins like
RAD51 and P/CAF, known to be involved in DNA damage
response pathways and DNA transcription in cells. In an
effort to elucidate the cellular function of BRCA2, we have
studied the interaction between BRCA2 and other cellular
proteins in mammary epithelial cells. The focus of our study
has been on interaction with other transcriptional factors in
the nucleus. Preliminary data indicate that BRCA2 interacts
with Stat proteins upon ligand stimulation. Identification of
proteins that interact with BRCA2 can shed light on its
physiological role in the development of breast cancer.
PIII-08 HerceptinTM (trastuzumab) in patients who overexpress Her-2 and have failed multiple
chemotherapy regimens for advanced breast cancer: a pragmatic study
G Westman
The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway
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PIV-03 Embryonic lethality in the Brca1-1700T mouse model suggests inhibition of p53-dependent
pathways
P Hohenstein*†, M Kielman*, C Breukel*, P Krimpenfort‡, A Berns‡, M Bennett¶, R Wiseman¶, C Cornelisse†, 
G-J van Ommen*, P Devilee*† and R Fodde*
*MGC Department of Human Clinical Genetics, LUMC, Leiden, †PGD Department of Pathology, LUMC, Leiden, ‡Department of
Molecular Genetics, Netherlands Cancer Institute, Amsterdam, The Netherlands, ¶Laboratory of Molecular Carcinogenesis, NIH,
Research Triangle Park, North Carolina, USA
The vast majority of mutations found in the human BRCA1
gene predict expression of a truncated protein, which may
retain one or more functional domains. To test the possi-
bility that truncated BRCA1 proteins might have a domi-
nant effect on wild-type BRCA1 or other proteins, we
generated a targeted mouse model, designated
Brca11700T, in which a neomycin resistance gene is
inserted in exon 20 of the murine Brca1 gene. This muta-
tion is predicted to result in expression of a mutant Brca1
protein which will not encompass the last BRCT repeat,
most likely resulting in disruption of the p53-specific trans-
activation domain. RT-PCR analysis confirmed that the
mutant transcript is expressed.
Mice heterozygous for this mutation do not show a predis-
position to tumorigenesis. Also g-radiation does not have a
significant effect on these mice. As has been reported for
the other Brca1 mouse models, homozygosity for this
mutation is embryonic lethal. However, the developmental
stage at which lethality occurs differs from the other
models. Preliminary results indicate that homozygous
Brca11700T embryos can reach headfold stage, although
not before 9.5 dpc, after which further development is
blocked or lethally impaired.
The observed embryonic phenotype resembles the one
found in compound Brca1–/–Tp53–/– embryos. This
might suggest that in the Brca11700T mouse model
embryonic lethality is caused by a combination of dis-
turbed dsDNA break repair and an impaired p53-depen-
dent response to the resulting genetic instability.
Possibly, p53 binds to the mutant Brca1 protein, which
still contains the p53-binding domain. However, since
the C-terminal p53 transactivation domain is likely to be
disturbed, this interaction might result in p53 being
blocked in an inactive complex. Recently, p53 was
shown to be able to lead to tumorigenesis by haploin-
sufficiency. The latter observation suggests that even a
partial sequestering of p53 by a mutant Brca1 protein
may result in a cellular phenotype.
PIV-04 Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients
J Alsner*, M Yilmaz*, P Guldberg†, LL Hansen* and J Overgaard*
*Aarhus University Hospital, Aarhus, †Danish Cancer Society, Copenhagen, Denmark
TP53 mutation is a strong independent marker for sur-
vival in breast cancer with some heterogeneity in the
clinical phenotype of various types of mutations. Based
on 315 patients with breast carcinoma, we suggest a
new model for the differentiation of TP53 mutations.
Although  TP53 mutation in general was associated with
aggressive tumour/patient characteristics, missense
mutations outside any conserved or structural domain
did not affect the clinical outcome (risk of disseminated
disease and death). In contrast, patients with missense
mutations affecting amino acids directly involved in DNA-
or zinc-binding displayed a very aggressive clinical phe-
notype. Null mutations (including missense mutations
disrupting the tetramerization domain) and the remaining
missense mutations displayed an intermediate aggres-
sive clinical phenotype. When patients were divided into
3 groups, (i) wild-type together with the missense muta-
tions outside structural/conserved domains, (ii) null
mutations and the missense with intermediate clinical
phenotype, and (iii) the very aggressive missense muta-
tions, disease-specific survival rates were 89%, 58%,
and 35% (5-year actuarial values, P < 0.0001), respec-
tively. In a Cox proportional hazards analysis, separation
of TP53 mutations according to these criteria eliminated
the prognostic importance of all investigated classical
factors except nodal status.
PIV-05 The GSTT1 genotype is associated with p53 mutation status of breast cancer tumours
K Gudmundsdóttir, L Tryggvadóttir and JE Eyfjörd
The Icelandic Cancer Society, Reykjavík, Iceland
The role of the glutathione S-transferases is to provide
protection against reactive mutagenic electrophiles by
catalysing their conjugation to glutathione. In humans
there are four classes of cytosolic GSTs, a (GSTA), m
(GSTM), p (GSTP) and q (GSTT). Homozygous deletions
of 50% and 20% of the genes coding for GSTM1 and
GSTT1, respectively, results in conjugation deficiency. An
A-G polymorphism at nucleotide 313 results in an amino
acid substitution (Ile105Val) in the substrate binding site
of the GSTP1 gene. The risk to the individual carrying aPIV-06 Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
A Langerød*, TI Andersen*†, I Bukholm*‡ and A-L Børresen Dale*
*Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, †Present address: Department of
Oncology, Ullevaal University Hospital, Oslo, Norway, ‡Present address: Department of Surgery, Akershus Central Hospital,
Lørenskog, Norway
Case-control studies have reported association between
polymorphisms in the TP53 gene and breast cancer [1].
We have examined whether certain alleles or haplotypes
show association with loss of heterozygosity (LOH) or
mutations in TP53. Our hypothesis is that certain alleles
may predispose for breast cancer through a mechanism
promoting LOH or mutations. 452 breast cancer patients
were genotyped for three intergenic polymorphisms [2–4]
and one polymorphism located downstream of the gene
[5]. The SNPs (Single Nucleotide Polymorphisms) in exon
4 and intron 6 were analysed using the restriction
enzymes BstUI and MspI respectively, while the 16 bp
insertion in intron 3 and the VNTR downstream of the
gene were examined using capillary electrophoresis. LOH
and mutation analyses have previously been performed in
samples from the same cohort. In conclusion, we were not
able to demonstrate any statistical significance implying
that any of these polymorphisms were associated with
increased risk of LOH or mutation of the TP53 gene.
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PIV-07 P53 mutations in breast and ovarian carcinomas from BRCA1 and 2 mutation carriers and
noncarriers
E Sensi, C Ghimenti, G Cipollini, D Iandolo, G Naccarato, P Viacava, G Bevilacqua and MA Caligo
Department of Oncology, Division of Pathology, University of Pisa, Italy
Breast and ovarian carcinomas occurring in carriers of
BRCA1 and 2 gene mutations may have a distinct
pathway of molecular pathogenesis from those occurring
in noncarriers. Data from murine models suggest that the
p53 gene, which is involved in initiating cell cycle arrest
and apoptosis in response to DNA damage, may be
important in the tumorigenesis of BRCA1 and 2-associ-
ated cancers, and its loss of function could be a early criti-
cal event in the malignant transformation of cells defective
for BRCA1 and 2 genes. Therefore, breast and ovarian
tumors from carriers of BRCA1 and 2 alterations might be
expected to exhibit a high rate of somatic p53 mutations.
An analysis was carried out on 84 Italian hereditary breast
and/or ovarian families to evaluate the frequency of
BRCA1 and  2 mutations by PTT and PCR-SSCP. 21 out
of 84 families showed disease-associated BRCA germline
mutations: 15 probands (18%) had BRCA1 mutations and
6 patients (7%) presented alterations in the BRCA2 gene.
In addition, 80% of mutations found in the BRCA1 gene
and 33% of alterations in the BRCA2 result in a premature
termination of translation. The frequency of p53 mutations
was then evaluated in 40 tumor DNAs from 33 out of 84
families analysed for BRCA1 and 2 gene alterations (8
were  BRCA1 mutation-carriers and 25 were noncarriers).
The tumor DNAs were screened for alterations in the
DNA-binding domain of the p53 gene (exon 5 through 8)
using PCR-SSCP. Direct sequencing was performed on
gene fragments that showed altered mobility in the PCR-
SSCP pattern. Mutations in the p53 gene were detected
in 4 out of 8 tumors from BRCA1 and 2 mutation carriers
(50%) versus 2 out of 32 carcinomas from noncarriers
(6%). All the observed mutations were single-base-pair
substitutions. One alteration affected the splice donor site
of exon 6, and it was present in a BRCA-negative family as
germline mutation. The expression of p53 protein in
BRCA-carrier and noncarrier tumors was analysed by
immunohistochemistry using the mouse monoclonal anti-
body DO-7. The same analysis was also performed in a
consecutive series of 72 sporadic tumors as a control
group. 5 out of 8 BRCA-carrier tumors (63%) and 2 out of
variant of one of these genes is estimated to be low, but
the high frequency in the population of some of these
variants makes the population attributable risk high. The
aim of this study is to investigate whether any associa-
tions exist between the above mentioned GST genotypes
and breast cancer, and whether they affect the p53 muta-
tion status of the tumours and penetrance of germline
mutations in the BRCA2 gene. The polymorphisms have
been analysed by PCR, electrophoresis and RFLP. No
significant differences have been observed between the
GST genotypes in the 258 controls and 450 cases
analysed so far. Both groups will be enlarged to increase
the power of the study. p53 mutations in breast cancer
tumours are significantly increased in individuals carrying
the GSTT1 null genotype, both alone and in combination
with the GSTP1 AG/GG genotype. The effect of the GST
genotypes on the penetrance of BRCA2 has to be
studied further.
http://breast-cancer-research.com/supplements/2/S1Breast Cancer Research    Vol 2 Suppl 1 The Second International Symposium on the Molecular Biology of Breast Cancer
32 BRCA-noncarrier carcinomas (6%) were positive for
p53 staining. Finally, 25 out of 72 sporadic tumors (35%)
had p53-positive immunostaining. A significantly higher
frequency of p53 mutation and overexpression was found
in the BRCA-associated tumors. Our data are in keeping
with the postulate that loss of p53 checkpoint control is
important in the molecular pathogenesis of breast and
ovarian carcinomas in carriers of BRCA1 and 2 mutations.
PIV-08 Screening breast cancer patients for Norwegian ATM mutations
K Laake*, P Vu*, TI Andersen†, B Erikstein‡, R Kåresen¶, PE Lønning§, E Skovlund†† and A-L Børresen-Dale*
*Department of Genetics, The Norwegian Radium Hospital, Oslo, †Department of Oncology, Ullevål University Hospital, Oslo,
‡Department of Oncology, The Norwegian Radium Hospital, Oslo, ¶Department of Surgery, Ullevål University Hospital, Oslo,
§Department of Oncology, Haukeland Hospital, Bergen, ††Clinical Research Office, The Norwegian Radium Hospital, Oslo, Norway
Heterozygosity for Ataxia Telangiectasia (AT), a cancer-
prone recessive syndrome, has been associated with an
increased risk of breast cancer. In the present study,
483 Norwegian breast cancer patients were screened
for carrier status of six different ATM mutations found in
Norwegian AT patients. One breast cancer patient
carried the Norwegian founder mutation, giving a point
estimate of the frequency of 0.2% (95% CI
0.01–1.2%). Assuming a 0.5% carrier frequency, the
present results are consistent with a maximum 2.4-fold
increased lifetime risk of breast cancer in ATM heterozy-
gotes. The study had 95% power to detect a 4.6-fold
elevated lifetime risk, and a 9-fold elevated risk in
women below age 55.
PIV-09 Constitutional alterations of the ATM gene in early-onset sporadic breast cancer
P Maillet*, H Bonnefoi† and A-P Sappino*
*Identification of Genetic Predispositions to Cancer Unit, Division of Oncology, †Gynecology and Obstetric Department, HCUG,
1211 Geneva 14, Switzerland
Since epidemiological evidence suggests that obligate
ataxia telangiectasia (A-T) heterozygotes are at
increased risk of developing breast cancer, we have
analysed the germline configuration of the ataxia telang-
iectasia mutated gene (ATM) in 26 premenopausal
breast cancer patients with no familial history of
breast/ovarian cancer and who developed breast cancer
before the age of 40. Five previously undescribed
germline sequence variants were detected by SSCP
screening of the 66 ATM exons. These included 3 rare
variants with an estimated allelic frequency of less than
1%: IVS59-20del4, IVS63+24delTT, and K1454N; 1
rare polymorphism (IVS56+23insT) with an estimated
allelic frequency of 2%; and 1 missense mutation
F1463C. We considered F1463C as a pathogenic
mutation because the same phenylalanine amino acid
substituted for a serine at this position is a known A-T
mutation. No sequence variant was found in a control
group of 45 healthy blood donors. These observations
support the hypothesis that constitutional alterations of
the ATM gene may contribute to the pathogenesis of
some early-onset sporadic breast cancer.
PIV-10 Modulation of ATM gene expression in a murine mammary epithelial cell line
GV Vutskits*, P Salmon†, JV Soriano‡, C Cudre-Mauroux†, D Trono†, R Montesano‡ and A-P Sappino*
*Division of Oncology, Department of Internal Medicine, HUG, 24, rue Micheli-du-Crest, 1211 Geneva 14, †Department of
Genetics and Microbiology and ‡Department of Morphology, University of Geneva Medical School, CMU, 1, rue Michel-Servet,
1211 Geneva 4, Switzerland
To explore the role of atm in epithelial cell biology, we have
used an in vitro model, in which non-transformed TAC-2
murine mammary epithelial cells recapitulate features of
normal breast epithelium differentiation, when grown in a
three-dimensional collagen gel. To modulate atm gene
expression or impair atm function we designed antisense
and dominant negative constructs which were delivered into
TAC-2 cells through conventional plasmids. However, since
these vectors failed to achieve effective long-term transgene
expression, we have then used lentiviral vectors to express
our constructs in TAC-2 cells with greater efficiency. We
plan to use this model to assess the impact of atm dysfunc-
tion on the following parameters: cell proliferation and sur-
vival, cell cycle progression and morphogenetic properties.
These investigations are expected to better delineate the
contribution of the atm gene as a cancer-predisposing gene
in the breast and to provide further insights into our under-
standing of atm function in epithelial cell biology.PIV-11 Loss of heterozygosity on chromosome arm 16q in breast cancer: clinical, molecular and
statistical approaches
A-M Cleton-Jansen*†, HM van Beerendonk*, NT ter Haar*, PHC Eilers‡, HC van Houwelingen‡, BA Bonsing*, VTHBM Smit*,
G-JB van Ommen† and CJ Cornelisse*
Departments of *Pathology, †Human and Clinical Genetics and ‡Medical Statistics, Leiden University Medical Center, Leiden,
The Netherlands
Loss of heterozygosity (LOH) on the long arm of chromo-
some 16 is one of the most frequent genetic events in
breast cancer, occurring in at least 50% of the breast
cancer cases. It is one of the earliest genetic events, occur-
ring already in the pre-invasive stage, in ductal carcinoma
in situ. Our study on flow-sorted tumour populations shows
that chromosome 16q loss occurs in the DNA diploid sub-
population of tumour cells, before aneuploidization, which
is also indicative of a role in early tumorigenesis.
A detailed LOH analysis using 30 highly polymorphic
markers and careful revision of the histology of a series of
200 primary invasive breast tumours could not demon-
strate any significant correlation between LOH on 16q
and histopathological markers. On the contrary there was
a markedly higher number of cases with 16q LOH in a
series of well differentiated pre-invasive breast cancers
when compared with poorly differentiated pre-invasive
tumours. This suggests a difference in time of occurrence
of 16q LOH in these two morphological distinguishable
groups, ie early LOH in well differentiated tumours and
late (upon invasion) in the poorly differentiated subset.
Since mapping of the smallest region of deletion involved
in LOH has not yet resulted in identification of the tumour
suppressor genes which are the target of 16q LOH, we
have applied a novel statistical approach for the analysis
of our data using an improved version of the model
described previously by Newton et al (Statist Med 1998,
17:1425). The program has been improved by introducing
the possibility for the existence of more than one tumour
suppressor locus and by increasing its speed by some
orders of magnitude. Analysis of 16q LOH data in breast
cancer with this program provides evidence for the pres-
ence of two different tumour suppressor loci on chromo-
some arm 16q.
PIV-12 Analysis of Fhit expression in stages of breast cancer progression
M Campiglio*, G Somenzi*, P Aiello*, F Wärnberg†, L Holmberg†, CM Croce‡ and S Menard*
*Molecular Targeting Unit, Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy, †Department of Surgery,
University Hospital, Uppsala, Sweden, ‡Kimmel Cancer Institute, Thomas Jefferson University, Philadelphia, PA, USA
The tumour suppressor gene FHIT, encompassing the
FRA3B fragile site on chromosome 3p14.2, is more than
1 Mb in size and encodes for a 1.1 kb cDNA. It belongs
to the histidine triad (HIT) superfamily and encodes a
cytoplasmic 16.8 kDa protein. Epithelial cells in most
human tissues strongly express Fhit protein, while Fhit
expression is absent or reduced in a large fraction of
tumours. Fhit protein reduction or absence occurs in
70% of breast cancer specimens, suggesting that alter-
ation of Fhit expression in this tumour is a frequent event,
caused by both alterations in the regulation of Fhit
expression and by the well documented biallelic deletion
of the gene. To determine how Fhit down-regulation influ-
ences breast cancer progression, we have examined
protein expression at different stages of the disease.
Starting from normal epithelia, we have also considered
morphological lesions of various grades, such as atypical
ductal hyperplasia (ADH), in situ breast carcinoma
(DCIS) and neoplasia. Preliminary data indicated that a
decrease or absence in Fhit protein expression is associ-
ated with high proliferation and large tumour size. Elec-
tron microscopy analysis has revealed that Fhit protein is
organised into small cytoplasmic clumps, mainly confined
to the end of a polymerised tubulin and to the plasma
membrane extroversion, suggesting a possible role of Fhit
in cytoskeleton structures.
Supported by AIRC.
PIV-13 Analysis of chromosome alterations and the E-cadherin and FHIT genes in lobular breast cancer
S Ingvarsson, C Huiping, JG Jonasson and BA Agnarsson
Department of Pathology, University Hospital, Reykjavik, Iceland
We have studied a set of 40 human lobular breast cancer
for LOH at various chromosome locations, including intra-
genic FHIT markers at chromosome 3p14.2, and for muta-
tions of the E-cadherin gene. A significantly lower level of
LOH was detected at chromosome arms, 1p, 3p, 9p, 11q,
13q and 18q in lobular compared to ductal breast tumours.
On the contrary, all lobular cases were found with LOH at
chromosome 16q22.1, containing the E-cadherin locus. A
significant association was detected between LOH at 3p
and high S phase, LOH at 9p and low ER and PgR
content, and between LOH at 17p and aneuploidy. LOH
within the FHIT gene was detected in 16% of the lobular
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cases, which is significantly lower than detected in ductal
breast cancer. A significant association was found
between LOH at the FHIT gene and reduced Fhit expres-
sion detected by IHC. The expression of Fhit was reduced
to a similar level in lobular and ductal breast cancer. Thus,
genetic alterations within the FHIT gene leading to loss of
Fhit proteins may play an important role in the carcinogene-
sis of a significant number of lobular breast cancers, even
though the frequency of alterations is lower than in ductal
breast cancer. Six novel mutations were detected within
the E-cadherin gene in combination with LOH of the wild
type E-cadherin locus and reduced E-cadherin expression.
LOH at 13q was significantly associated with LOH at 7q,
LOH at 11q and E-cadherin gene mutations. We conclude
that there is a molecular difference in the pathogenesis of
lobular and ductal breast cancer.
PIV-14 Excluding TTC4 as a target for loss on chromosome 1p31 in human breast cancer
Y Hey, W Brintnell, L James and J Varley
Cancer Genetics Group, Paterson Institute for Cancer Research, Wilmslow Road, Manchester, UK
We have previously reported a region of high loss of het-
erozygosity in human breast cancer on chromosome
1p31.1. Recently a new member of the human tetratri-
copeptide repeat-containing gene family, TTC4, was
mapped to a YAC 879a6 which encompasses the smallest
region of overlapping loss (SRO) reported by our group.
This therefore became a candidate for a new breast cancer
tumour suppressor gene. We used multiple pairs of PCR
primers from the gene to screen CEPH and Zeneca YACs
covering the region, but were unable to amplify a product
from any of them, including two independent isolates of
YAC 879a6. We have isolated both a BAC (31C23) and
YAC (13EA7) using primers from the 3¢ untranslated region
of TTC4. In single and double FISH experiments both
13EA7 and 31C23 located on chromosome 1p but distal to
879a6 at 1p31.3. This localisation was confirmed by
screening a panel of monochromosome hybrids. Compari-
son of TTC4 sequence with the genome database identified
a match between the 3¢ untranslated region of the gene and
EST WI-9676. However, this EST was assigned to chromo-
some 7 by radiation hybrid mapping, transcript and YAC
contig mapping. We therefore identified YACs from these
contigs using primers from WI-9676 and sequenced the
resulting PCR products. These revealed a number of
nucleotide alterations that suggested that the sequence on
chromosome 7 is a pseudogene. Finally pseudogene-spe-
cific primers were used to identify two new BACs, one of
which (51H8) was localised to 7p13-14 by FISH. In conclu-
sion, we have therefore reassigned TTC4 by FISH to
1p31.3, excluding it as a target for inactivation in human
breast cancer at 1p31.1, and identified a TTC4 pseudo-
gene that maps to chromosome 7p13-14.
PIV-15 A detailed physical map of a region within human chromosome 16q22.1
E Frengen*, P Rocca-Serra†, S Shaposhnikov*, L Taine‡, J Thorsen*, C Bépoldin†, M Longy†, H Prydz* 
and F Dorion-Bonnet†
*The Biotechnology Centre of Oslo, University of Oslo, Norway, †Laboratoire d'Oncologie Moléculaire, Institut Bergonié,
Bordeaux, France, ‡Laboratoire de Cytogénétique, Centre Hospitalier Universitaire Pellegrin, Bordeaux, France
We have previously described a tight cluster of five appar-
ently unrelated genes on human chromosome 16q22.1.
An expanded region surrounding this gene cluster has
now been mapped using P1 artificial chromosome clones
(PACs). This PAC map is currently used to identify and
characterize new genes from the q22.1 region of human
chromosome 16. Work is also underway to reveal the
functions of selected genes in the contig.
The construction of the contig was performed by using
probes derived from the end of the starting PACs in
repeated library screening. If the region mapped contains
large duplicated sequence elements, this chromosome
walking could potentially lead to the extension of the map
into unlinked chromosomal regions. Such large duplicated
sequences of several tens of kilo base pairs, which are
shared by several human chromosomes, have previously
been reported. To verify the organization of the PAC map,
we have therefore performed long-range mapping experi-
ments. High molecular weight human genomic DNA was
digested with a panel of rare-cutting restriction enzymes,
separated by PFGE, blotted and hybridised with selected
probes from the contig. These results demonstrated that
the contig faithfully represents the chromosomal region
covered by the PACs. Furthermore, clusters of restriction
sites for CpG cutters are strong evidence for the pres-
ence of CpG islands, which are landmarks for genes.
Therefore, the mapping experiments have also resulted in
the identification of several genes within human chromo-
some 16q22.1.
This work is supported by grants from The Norwegian Research Council
and The Norwegian Cancer Society (EF and HP), and The Comité du Lot-
et-Garonne de la Ligue Nationale Contre le Cancer (ML and FDB). PRS
was a recipient of an ARC fellowship.PIV-16 Expression of variant forms of the MUC1 gene correlates with the invasiveness of breast cancer
cells
R Zeillinger, B Schmid, D Tong, B Fasching, I Schiebl, M Stimpfl, A Obermair and S Leodolter
University of Vienna, Department of Obstetrics and Gynecology, Division of Gynecology, Molecular Oncology Group, A-1090
Vienna, Waehringer Guertel 18-20, Austria
The characterization of tumor markers is of prime impor-
tance in understanding the mechanisms underlying cancer
initiation and progression. The most exclusively used
marker for monitoring breast cancer patients are the
protein products of the MUC1 gene, which is strongly
overexpressed in breast cancer cells. The best character-
ized MUC1 gene product is MUC1/REP (episialin, PEM,
CA15-3, MCA). It is important in reducing cell-cell and
cell-extracellular matrix interactions, probably being
involved in the spread of cancer cells from the primary
tumor. MUC1 overexpression was found to correlate with
invasiveness. Four isoforms are generated by differential
splicing due to the use of alternative splice acceptor sites
for exon 1. These were designated variants A to D. A
higher expression of variant A than of variant B was found
to indicate thyroid papillary carcinomas.
We investigated the expression of these variant forms in
23 permanent breast cell lines. RNA samples were ana-
lyzed by RT-PCR and subsequent automated quantitative
fragment analysis. The cell lines were also analyzed for
invasiveness by an in vitro collagen invasion assay. Ten
cell lines showed invasive growth, either as single cells or
as cell clusters. Variant A was solely expressed in four of
the invasive cell lines and was preferentially expressed in
one line (ratio 35.1), whereas only 1 out of 13 non-inva-
sive cell lines expressed more variant A than variant B
(ratio 1.1). This correlation between the mRNA expres-
sion of variant A and the in vitro invasiveness was statisti-
cally significant (P = 0.035). Moreover, variant D was
concomitantly found with the preferentially expressed
variant A.
This is the first report about the correlation of expression
of a MUC1 splice variant and the invasiveness of breast
cancer cells. We conclude that not only overexpression of
MUC1 in cancer cells is responsible for metastasis, but
also the expression of variant forms.
PV-01 p16INK4A as a predictive factor in patients with locally advanced breast cancer treated with
neoadjuvant doxorubicin monotherapy
S Geisler*, B Smith-Sørensen†, D Betticher‡, IK Bukholm†¶, LA Akslen§, A Kappeler‡, M Gugger††, PE Lønning*
and A-L Børresen-Dale†
*Department of Medicine, Section of Oncology and § Pathology, Haukeland University Hospital, Bergen, †Department of
Genetics, The Norwegian Radiumhospital, Oslo, Norway, ‡Institute of Medical Oncology and ††Pathology, University of Bern,
Switzerland
The cyclin-dependent kinase inhibitor p16 (p16INK4A/
CDKN2A) binds to Cdk4 and inhibits the formation of
the Cdk4/cyclin D1 complex, thereby inhibiting the cyclin
D-dependent phosphorylation of the retinoblastoma
protein (pRb). Phosphorylation of pRb leads to release of
the E2F transcription factor that activates genes promot-
ing cell cycle progression from G1 to S-phase. Alter-
ations of p16INK4A, leading to its inactivation, result in the
deregulation of cell proliferation through loss of G1
arrest control, and can thereby contribute to the forma-
tion of cancer and may influence tumour response to
chemotherapy. To investigate the role of p16INK4A as a
predictive factor in the neoadjuvant treatment of patients
with breast cancer, we have analysed the p16 status in a
series of 91 patients treated for locally advanced breast
cancer with doxorubicin monotherapy. We measured
p16INK4A protein expression with use of immunohisto-
chemistry, studied possible mutations by direct sequenc-
ing of exon 1 and 2, and determined the methylation
status of CpG sites in exon 1a. Of 90 tumours examined
by immunostaining, 28 were negative or expressed
p16INK4A at low levels (grade 1 = <5% positively stained
tumour cells), 35 had a moderate p16INK4A expression
(grade 2 = 5–50% positively stained tumour cells), and
27 had strong expression of p16INK4A (grade 3 = >50%
positively stained tumour cells). One tumour had a mis-
sense mutation in codon 145 in addition to methylation
of exon 1a (p16INK4A immunostaining grade 3), and three
tumours displayed methylation of exon 1a (2 showed
p16INK4A immunostaining grade 1, and 1 showed p16INK4A
immunostaining grade 2). One tumour with methylation
of exon 1a has previously been reported to have a muta-
tion of TP53 affecting the L2/L3 domains. p16INK4A
methylation correlated with lack of response to doxoru-
bicin treatment; 2/4 patients with p16INK4A methylation
progressed on therapy, compared to 7/86 without
p16INK4A methylation (P = 0.048). On the contrary,
p16INK4A immunostaining did not correlate with treatment
response, nor with immunostaining for pRb, p19ARF,
cyclin D1 and cyclin E, nor mutational analyses for TP53.
Our data suggest that p16INK4A alterations may be
involved in chemoresistance in breast cancer, although
immunostaining alone fails to show a predictive value for
response to doxorubicin treatment.
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PV-02 Low frequency of p16INK4a promoter methylation in mammary carcinomas as revealed by positive
display of methylated sites
R Lilischkis, H Kneitz and H Kreipe
Institute of Pathology, Hannover Medical School, Hannover, Germany
Promoter methylation represents an important mechanism
for silencing gene expression in higher eukaryotes. In
order to study methylation of the promoter of the tumour
suppressor p16INK4a, we developed a fast and simple
method that in contrast to previous studies relies on the
positive display of methylated sites (PDM). The method is
based on bisulphite treatment of DNA, PCR-amplification
of the modified DNA, and restriction digest of de novo
created restriction sites to positively display DNA methyla-
tion in a background of unmethylated DNA. Since methy-
lated as well as unmethylated DNA is amplified, informa-
tion on the proportion of both is provided.
Using this approach, we analysed 33 ductal invasive
mammary carcinomas, 4 normal mammary tissues and 4 cell
lines for methylation. p16INK4a methylation was detected in
1/33 carcinomas (3%) and in 0/4 normal tissue samples.
We conclude that PDM provides a useful tool for determin-
ing the degree and pattern of promoter methylation and is
suitable for screening large series of tissue samples.
PV-03 Estrogen-dependent c-jun upregulation may control cyclin D1 expression
MD Planas-Silva, J Liu Donaher and RA Weinberg
Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA
Estrogen controls the proliferation of estrogen-receptor
positive breast cancer cells. In an effort to understand how
estrogen promotes cell-cycle progression we and others
have found that expression of the cell-cycle regulator cyclin
D1 is tightly controlled by estrogen in MCF-7 cells.
However, stable expression of the estrogen receptor in dif-
ferent cell lines is not sufficient to allow estrogen-dependent
cyclin D1 expression. This lack of cyclin D1 upregulation in
cells stably expressing estrogen receptor (ER) may explain
why estrogen cannot induce proliferation in these cells. To
further understand the molecular mechanisms by which
cyclin D1 is regulated in response to estrogen, we have
characterised in more detail the response of HaCaT cells
expressing ER to estrogen, and compared them with those
observed by MCF-7. Differential activation of AP-1
members is seen after estrogen treatment of MCF-7. This
MCF-7 specific upregulation of c-fos and c-jun precedes
and correlates well with cyclin D1 induction by estrogen.
Further studies using the cyclin D1 promoter indicate that c-
jun upregulation by estrogen may induce cyclin D1 expres-
sion and most likely cell cycle progression. Therefore, we
suggest that the ability of MCF-7 cells to activate c-jun in
response to estrogen is crucial to understanding the estro-
gen-dependent proliferation of breast cancer cells.
PV-04 Negative regulation of p53 expression is an essential, rate-limiting function of Jun in the control
of cell cycle progression
M Schreiber*†, F Piu‡, A Kolbus¶, A Szabowski¶, U Möhle-Steinlein†, J Tian‡, M Karin‡, P Angel¶ and EF Wagner†
*University of Vienna, Department of Obstetrics and Gynecology, Division of Senology, Vienna, Austria, †Research Institute of
Molecular Pathology (IMP), Vienna, Austria, ‡University of California at San Diego, Department of Pharmacology, La Jolla, CA,
USA, ¶Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany
The tumor suppressor gene p53 is inactivated by mutations
in >50% of human tumors, including breast cancers. Here
we show that p53 expression is negatively regulated by the
Jun proto-oncogene, which encodes a component of the
mitogen-inducible immediate-early transcription factor AP-1
and has been implicated as a positive regulator of cell prolif-
eration. In fibroblasts derived from Jun-/- mouse fetuses, the
tumor suppressor gene p53 and its target gene, the CDK
inhibitor p21, are expressed at elevated levels, whereas
overexpression of Jun represses p53 and p21 expression.
Surprisingly, protein stabilisation, the common mechanism
of p53 regulation, does not seem to be involved in upregula-
tion of p53 in Jun-/- fibroblasts. Rather, Jun was found to
negatively regulate transcription of p53 by direct binding to
a conserved AP-1 site in the p53 promoter. Furthermore,
overexpression of Jun accelerates cell proliferation, whereas
the absence of Jun results in a severe proliferation defect
and a prolonged crisis prior to spontaneous immortalisation.
The cyclin D1- and cyclin E-dependent kinases (CDKs) and
transcription factor E2F are poorly activated, resulting in
inefficient G1 to S-phase progression. Importantly, deletion
of p53 abrogates all defects of Jun-/- cells in cell cycle pro-
gression, proliferation, immortalisation, and activation of G1
CDKs and E2F. These results demonstrate that the sole
rate-limiting function of Jun in fibroblast proliferation is nega-
tive regulation of p53 expression, and establish a mechanis-
tic link between Jun-dependent mitogenic signalling and cell
cycle regulation.PV-05 Setting up an efficient and reliable screening method for novel c-Jun N-terminal kinase
substrates
T Kallunki*, C Holmberg*, M Lerdrup-Hansen*, T Herdegen†, A Aronheim‡ and M Jäättelä*
*Danish Cancer Society, Copenhagen, Denmark; †Christian-Albrechts University of Kiel, Germany; ‡B Rappaport Faculty of
Medicine, Technion-Israel Institute of Technology, Israel
The c-Jun N-terminal kinase (JNK), also known as the
stress activated protein kinase (SAPK), forms a family of
serine-threonine kinases that can be efficiently activated
by both mitogenic and apoptotic signals. Moreover in
various cases JNK activation has been shown to have both
preventative and causative roles in apoptosis. Thus far the
best characterized target of JNK is c-Jun, which forms a
part of the transcription factor AP-1. It is a well established
fact that the activation of JNKs in the cell will lead to the
phosphorylation of Ser63 and Ser73 at the c-Jun activa-
tion domain. This in turn results in the transcriptional acti-
vation of the AP-1 responsive genes. We show here that,
in some cancer cell lines, JNK activation does not always
correlate with AP-1 activation. This lack of AP-1 activation
is also associated with the lack of the phosphorylation of
c-Jun. We have been testing two different ‘substrate
screening systems’ in order to find novel, relevant JNK
substrates from these cancer cells.
PVI-01 Angiogenesis in breast cancer: establishing a link between angiogenesis and hormone
regulation
R Soares, C Costa, F Gärtner and F Schmitt
Institute of Molecular Pathology and Immunology of the University of Porto - IPATIMUP, Porto, Portugal
Angiogenesis is a process of formation of new blood
vessels that is essential for tumour growth and metastasis.
There is recent evidence indicating that angiogenesis can
be regulated by hormones. The aim of our study was to
evaluate the effect of oestrogen in angiogenesis using a
hormone-dependent cancer model, breast cancer. We
studied two different breast cancer cell lines (one hormone-
dependent, MCF7, and one hormone-independent,
Hs578T), that were inoculated in the mammary fat pad of
nude mice. The mice were treated with oestrogen and the
tumours were removed when they reached 80 mm3. Angio-
genic index, VEGF and TGFa were evaluated by immuno-
histochemistry and Western blotting. The MCF7 tumours
had a higher microvessel density and expressed both VEGF
and TGFa. In contrast, Hs578T, xenografted in mice, pre-
sented a lower angiogenic index, expressed VEGF, but did
not express TGFa. We also studied a series of 86 human
breast carcinomas and demonstrated a significant associa-
tion between TGFa and angiogenic index: TGFa+ cases,
48.1 ± 28.0; TGFa– cases, 31.8 ± 20.0 microvessel
density (P = 0.01). Since by binding to its receptor, oestro-
gen induces the transcription of TGFa, our results suggest
that TGFa is a putative factor linking hormone regulation
and angiogenesis in breast cancer.
PVI-02 Development of a high throughput, molecular diagnostic assay for predicting telomerase activity
in breast cancer cell lines and tissues
L Elmore*, A Akalin*, L Gollahon¶, G Clarke§, M Grimes*, RT Burks*, A Ferreira-Gonzalez*, C Garrett*‡ and S Holt*†‡
*Departments of Pathology and †Human Genetics, ‡Massey Cancer Center, Medical College of Virginia Campus at Virginia
Commonwealth University, Richmond, VA, ¶Department of Biological Sciences, Texas Tech University, Lubbock, TX; §Baylor
College of Medicine, Houston, TX, USA
Telomerase is a cellular enzyme that helps to provide
genomic stability in tumor cells by maintaining the
integrity of telomeres. Telomerase is an RNA-dependent
DNA polymerase that contains a protein component
(hTERT) and an associated RNA (hTR), which is used as
a template for telomere repeat addition. Telomerase activ-
ity, while not detectable in most normal human somatic
cells, is associated with approximately 85% of malignant
human cancers overall, including over 90% of breast
cancers.
We have optimized a novel, quantitative, high-throughput
telomerase activity assay using fluorescently labelled
primers and Real Time quantitation via the ABI Prism
7700 (a.k.a., the TaqMan). Using established breast
cancer cell lines and a subset of breast tumors, we
demonstrate that telomerase levels quantitated from the
TaqMan-based assay closely correlate with values
obtained using the traditional, gel-based telomerase activ-
ity assay (TRAP). In addition, we have assessed the levels
of both hTERT mRNA and hTR in each of our samples via
RT-PCR to determine whether relative amounts or a ratio
of the two telomerase components correlate with activity
in a given sample. Our ultimate goal is to develop a Real
Time, fluorescent RT-PCR assay to simultaneously
measure hTERT and hTR messages in breast tumor
samples, in an attempt to convert the enzymatic telom-
erase activity assay into a quantitative nucleic acid test to
predict levels of activity in routinely processed clinical
specimens.
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PVI-03 Mammary epithelial cells immortalized by over-expression of the catalytic subunit of human
telomerase may represent a model for mammary epithelial differentiation
J DiRenzo, R Rivera-Gonzalez and M Brown
Dana Farber Cancer Institute, Boston MA, USA
Retroviral transfer of a cDNA encoding human Telomeric
End Reverse Transcriptase (hTERT) into primary human
mammary epithelia has led to the establishment of several
clonally derived lines of Immortalized Mammary Epithelial
Cells (IMECs). Unlike their empty vector control counter-
parts, the IMECs were capable of bypassing replicative
senescence. In doing so, they exhibited a marked
decrease in the protein levels of the retinoblastoma gene
product, Rb, and a complete loss of the cyclin-dependent
kinase inhibitor p16, events which are hallmarks of the
immortalization process. In culture, IMECs proliferate in a
manner that is dependent on insulin and Epidermal
Growth Factor (EGF). Interestingly, these IMECs can be
induced to undergo a differentiation which is character-
ized by an arrest of the cell cycle in G1 and the loss of
cyclin D1 expression. During this differentiation process,
IMECs establish cell–cell interactions that lead to an
ordered arrangement of cells in two dimensions. Further
genetic and biochemical characterization may hopefully
reveal the nature of these differentiated IMECs.
PVII-01 Molecular analyses of human breast cancer metastasis: genetic markers of progression
K Driouch and R Lidereau
Centre Rene Huguenin, St. Cloud, France
Breast tumorigenesis and metastasis result from an accu-
mulation of genetic alterations involving ‘cancer genes’. The
prognostic value of these genetic alterations has been
greatly investigated. However, few of them have been
studied in secondary tumors, owing to the limited availability
of surgical specimens. In human cancers, the genetic mech-
anisms underlying the metastatic process are still poorly
understood. We investigated whether certain recurrent
alterations could be associated with the metastatic process.
We analysed the genetic profiles of primary tumors, local
recurrences, and distant metastases of breast cancer. The
alteration profiles in these 3 types of samples were different,
suggesting distinct mechanisms of progression.
MYC, ERBB2 and CCND1 amplification is rare in distant
metastases of breast cancer. These genetic amplifications
could be involved in the genesis of primary tumors, but
less in the later stages of breast cancer progression. In
contrast, LOH is a frequent genetic event in breast cancer
metastases. The LOH regions frequently observed in
primary breast tumors are also detected in breast cancer
metastases, mostly due to a clonal evolution of metastatic
cells from the primary site to the metastases, but specific
altered regions could also be acquired during metastatic
progression. LOH analyses have defined regions of dele-
tion associated with metastasis on several chromosomal
regions, ie 3p21.3, 7q31, 15q14, 16q22.1 and 16q23.2.
These regions contain several candidate metastasis sup-
pressor genes such as DLC1, RPL14, DEF3, CTNNB1,
MET,  THBS1,  CDH1. Other metastasis-related genes
such as NME1 and KAI1 show losses of expression that
do not correlate with LOH. Other genetic mechanisms
could be involved. These studies could lead to the charac-
terisation of new genomic markers of tumor aggressive-
ness and enhance our understanding of the molecular
mechanisms of metastasis and cancer progression.
PVII-02 AKT-1 and BCL-2 co-expression in breast cancer patients correlates with better survival
G Pérez-Tenorio, O Stål and the Southeast Sweden Breast Cancer Group
Department of Oncology, Faculty of Health Sciences, Linköping University, Linköping, Sweden
Background and purpose: Akt-1 is a serine/threonine-
protein kinase that regulates growth factor-dependent
cell proliferation and survival. Activated-Akt-1 causes
Bcl-2 release from the BAD:Bcl-2 inactive complex. Bcl-
2 is not only able to prevent apoptosis, as a down-
stream effector of Akt-1, but also can delay cell-cycle
progression. Akt-1 is over-expressed in breast cancer
cell lines and tumours, while Bcl-2 has been related with
tumour survival and drug resistance in vitro and to an
ER+/well differentiated sub-group of tumours, in vivo.
Since endocrine treatment effectiveness could be due
to activation of the apoptotic program, we wanted to
investigate the expression and relationship between
these factors as well as other variables (C-erbB-2, ER,
and S-phase).
Patients and methods: Frozen tissue from primary tumours
of 104 breast cancer patients (age <50 years), who
received tamoxifen, zoladex or both (follow-up period >10
years), was used to determine the expression of Bcl-2 and
Akt-1 by immunohistochemistry. C-erbB-2 expression and
S-phase were analysed using flow cytometry. The statistical
analysis was performed using the ‘Statistica’ package.
Results: There was a positive correlation between Bcl-2
and Akt-1 expression (38 Akt-1+/65 Bcl-2+ comparedwith 11 Akt-1+/37 Bcl-2- cases, P = 0.007). This correla-
tion also appears in metastasis-free patients (P = 0.0008)
but not in those patients with metastasis (P = 1.0). Bcl-2
alone was not significantly associated with ER, S-phase or
c-erbB-2 expression (P > 0.05) but a trend was observed
for Bcl-2-positive cases to present ER+/low-S-phase/C-
erbB-2-negative phenotypes. In terms of distant-recur-
rence-free survival, those patients expressing Akt-1+/
Bcl-2+ survived longer than Akt-1+/Bcl-2- patients
(P = 0.028) while no benefit was observed for Bcl-2
(P = 0.6) or Akt-1 (P = 0.9) individually.
Conclusions: The results suggest that Akt-1 might rein-
force the prognostic value of Bcl-2, and probably this phe-
notype characterises a subgroup of patients less prone to
undergo metastasis.
PVII-03 Does a polymorphism in the CYP17 gene predict mammographic density?
G Ursin, SA Ingles, H Spencer Feigelson, GA Coetzee, L Bernstein, MC Pike and A Buley
University of Southern California, Preventive Medicine, Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Los
Angeles, CA 90089, USA
Mammographic density has been associated consistently
with breast cancer risk in epidemiological studies. We and
others have shown that hormonal status is associated with
mammographic density. A pilot study was conducted to
determine if a known polymorphism in a gene, CYP17,
involved in the biosynthesis of female sex steroids, plays a
role in mammographic density. The CYP17 gene encodes
the cytochrome P450c17 enzyme which mediates the
17a-hydroxylation of pregnenolone and progesterone, and
subsequent conversion of these 17-hydroxylated products
to the estradiol precursors DHEA and androstenedione. In
the 5¢-UTR region of the CYP17 gene, a C/T single
nucleotide polymorphism (SNP) results in two alleles des-
ignated A1 and A2. The A2 allele has been associated
with higher circulating hormone levels in both pre-
menopausal and postmenopausal women.
We used data from 94 breast cancer cases aged 40 to
64, diagnosed between 1994 and 1998, who partici-
pated in the Los Angeles part of the population-based
Women’s Contraceptive and Reproductive Experience
(CARE) case-control study. We obtained blood samples
from the cases, and scanned mammograms obtained
prior to diagnosis (some as long as 5 years before). Mam-
mographic density was determined using a method we
have published previously. Subjects were genotyped for
the CYP17 SNP using genomic DNA from blood.
The mean percent density in the three groups of women
with the A1A1, A1A2 and A2A2 alleles were similar
(25.4%, 25.3% and 29.3%). However, compared with
women with the A1A1 genotype, the odds ratios (and
95% confidence intervals) of having a dense mammogram
(>50% mammographic density) in women with the A1A2
or A2A2 genotype were 3.9 (0.8–19.3) and 5.6 (0.8–9.6)
respectively, (P for trend = 0.09). The results suggest that
CYP17 may be associated with mammographic density,
possibly via its effect on estrogen levels.
PVII-04 Ribozymes targeting the tumor suppressor BRCA1 lead to increased chemosensitivity to
cisplatin and etoposide and chemoresistance to microtubule-interfering agents in HBL100 breast
cancer cell line
S Lafarge, M Ferrara and YJ Bignon
Laboratory of Molecular Oncology EA2145, Centre J Perrin, BP392, 58 rue Montalembert, 63011 Clermont-Ferrand Cedex1, France
BRCA1 is a cancer susceptibility gene involved in about 45%
of the familial breast cancers and 80% of families predis-
posed to breast and ovarian cancer. BRCA1 codes for a
protein of 1863 amino acids with multiple functions, including
DNA repair, activation of transcription, control of cellular prolif-
eration and involvement in apoptosis. In keeping with these
diverse functions, BRCA1 interacts with several proteins
including hRad51, complex hRad50-hMre11-p95/nibrin, and
gamma-tubulin. We developed an antisense strategy using
hammerhead ribozymes against this gene to understand the
roles and the functions of BRCA1. As BRCA1 is involved in
DNA repair, our first goal is to evaluate the sensitivity of
ribozyme-treated cells to chemotherapeutic drugs.
We designed and tested 3 ribozymes in cell-free extracts.
We cloned the two most efficient ribozymes into the retrovi-
ral vector LXSN and transfected them by lipofection in the
HBL100 cell line. We performed Real-Time quantitative PCR
to measure the expression of BRCA1 mRNA vs 18S rRNA,
and examined the protein level by western blot analysis. We
have found four clones with an inhibition of BRCA1 mRNA
expression between 82 and 99% which correlated with the
protein level. We tested the sensitivity of these clones to dif-
ferent drugs (doxorubicin, etoposide, cisplatin, taxol and vin-
cristine) by the sulforhodamine B proliferation test. The
decrease in expression of BRCA1 led to sensitivity to DNA
damaging agents (cisplatin and etoposide) and resistance to
microtubule-interfering agents (MIA) (taxol and vincristine).
No difference was found for doxorubicin treatment.
Our results with etoposide and cisplatin are consistent
with the role of BRCA1 in DNA repair. The results with
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PVII-05 Cytokeratin and mammaglobin as tumor markers in patients with high risk breast cancer
PF Ferrucci, C Rabascio, C Corsini, F Tealdo, M Paolucci, F Bertolini, H El Taani and G Martinelli
European Institute of Oncology, Milan, Italy
Aims of the study: To investigate the incidence and prog-
nostic relevance of tumor micro-contamination in BM
and/or G-CSF-mobilized peripheral blood progenitor cells
collections of stage II–III breast cancer patients.
Patients and methods: Patients were enrolled from Sep-
tember 1998 through May 1999 and underwent high-dose
chemotherapy with autologous PBPC transplantation. We
analysed a total of 71 patients for TC on PBPC apheresis
(28 of them had previously frozen samples). 43/71 patients
also had their BM evaluated on the day of the first PBPC
collection after 5 days of G-CSF administration (BM-STIM)
and immediately before HDCT (BM-PRECT). Cytokeratin
(CK) expression was evaluated in all samples by either
immunocytochemistry (ICC, sensitivity 1 × 10–6 cells,
9–16 × 10–6  cells for each sample) and reverse transcrip-
tase nested PCR (RT-PCR, sensitivity 1 × 10–7 cells).
Amplified products were then annealed to a 32P-labelled
internal sequence probe to confirm specificity. 41 patients
were also evaluated by nested RT-PCR for Mammaglobin
(MAM, sensitivity 1 × 10–6 cells) gene expression.
Results: (1) PBPC frequency of CK+ was 11% by ICC
and 66% by RT-PCR on 71 patients’ samples; (2)
BMSTIM and BMPRECT frequency of CK+ was 7–14%
by ICC and 65–60% by RT-PCR on 43 patients’ samples;
(3) all CK ICC+ samples were MAM RT-PCR+; (4) 53%
of patients with CK RT-PCR+ BM-STIM had their PBPC
and BM-PRECT CK RT-PCR+; (5) after a median follow-
up of 21 months on 28 patients with frozen samples, 25%
of patients relapsed and 43% of them had contaminated
PBPC; (6) 74% of CK ICC+ samples were CK RT-PCR+;
(7) BMSTIM, PBPC and BMPRECT frequencies of MAM+
were 15, 17 and 22% respectively by RT-PCR on 41
patients’ unfrozen samples; (8) PBPC frequency of MAM+
was 20% by RT-PCR on 25 patients’ frozen samples.
Conclusion: (1) MAM gene evaluation could add a lot of
sensitivity and specificity to the overall results. (2) G-CSF
administration for PBPC mobilization does not increase
PBPC contamination. (3) A longer follow-up of these
patients is needed to evaluate the prognostic relevance of
different markers of tumor cell contamination in HDCT for
breast cancer.
PVIII-01 Promising method for DNA extraction from paraffin embedded archive material
A Bregård, P Vu, G Geitvik and A-L Børresen-Dale
Department of Genetics, The Norwegian Radium Hospital, Oslo, Norway
Formalin-fixed, paraffin-embedded materials are an invaluable
source for mutation analysis. However, DNA extraction from
this type of material can be challenging as well as time con-
suming. DNA extracted from paraffin-embedded material is
often highly fragmented and contaminated by protein agents.
For DNA analysis, such as PCR (polymerase chain reaction),
subsequent TTGE (temporal temperature gradient elec-
trophoresis) and DNA sequencing, optimal conditions
require long DNA fragments (200–1000 bp) and a DNA
with high purity with an OD ratio (abs. at 260 nm/abs at 280
nm) between 1.6 and 2.0. We have evaluated and combined
different protocols to get the highest quality and yield of
DNA. 5–10 mm × 8–10 sections of tissue were used.
The best results were achieved from extractions using rel-
atively high volumes (8–10 ml) of xylene and ethanol for
the deparaffinization and rehydration steps initiating the
extraction protocol. Furthermore, limiting the incubation
period for proteinase K digestion of the material to
4–8 hours yields longer fragments of DNA than prolonged
digestion. This, however, demands a prolonged incubation
period with lysis buffer, up to 24 hours, previous to diges-
tion. The phenol/chloroform extraction step in the tradi-
tional extraction procedure contains several uncertain
elements, risking protein contamination from the inter-
phase between the aqueous and organic phases, and the
phenol health hazards are also considerable. Using a PLG
(phase lock gel) tube from Eppendorf, in which a gel plug
separates the organic phase and the aqueous phase,
greatly eases the extraction and increases DNA yield and
purity. The organic phase is locked underneath the gel,
leaving no room for protein contamination when pipetting
off or decanting the upper, aqueous phase. The health risk
posed by the solvent vapour released during the isolation
of the aqueous phase is also minimised by the gel barrier.
Subsequent salt precipitation with 1 M NaCl and ethanol
‘rinse’ is performed before the samples are air-dried and
diluted in 100–200 ml 1 × TE buffer. DNA yield and quality
were evaluated by a spectrophotometer, a fluorometer and
PCR fragments separated on an agarose gel followed by
EtBr staining. The OD ratio 260/280 nm of the extracted
DNA was 1.67–1.97 for different batches. Six out of 10
MIA are more unexpected. The observed chemoresis-
tance may be related to the interaction of BRCA1 with
gamma-tubulin, a component of the mitotic spindle. The
function of BRCA1 in this pathway must be investigated
further to understand this modification of chemosensitiv-
ity.samples yielded PCR products with fragments as long as
770 bp. A multiplex PCR for 6 exons of the ATM gene
was performed with success. Previously extracted DNA
from the same type of tissue block using different proto-
cols yielded no PCR products for the same multiplex
PCR.
This reliable method of extraction, although a bit time con-
suming, makes analysis of paraffin-embedded material
possible, yielding satisfactory results for further study of
the DNA. This protocol will now be used for detection of
ATM mutation carriers among family members of AT chil-
dren who have died of cancer.
PVIII-02 REAL Real-Time!
F Boeckman, L Tan and K Hamby
Bio-Rad Laboratories, 2000 Alfred Nobel Drive, Hercules, CA 94547, USA
Recent advances in real-time PCR analysis have led to
significant improvements in the accuracy and simplicity
of DNA quantification and gene expression analysis.
Here we demonstrate the new Bio-Rad iCycler iQ
system capabilities. When PCR is conducted on 96
replicates, we achieve a uniformity with a CV of less
than 1%, consistent with that of other well-known
systems for real-time PCR analysis. We demonstrate
the ability to distinguish a two-fold dilution series of
human genomic DNA down to 125 genomic equiva-
lents. We also show a wide dynamic range over which
quantification is possible, beginning with plasmids or
genomic DNA. The iCycler iQ system is designed to
work with many detection strategies; here we show the
iCycler iQs’ ability to employ a variety of techniques,
including SYBR Green I, TaqMan® and Molecular
Beacons. Finally, the iCycler iQ’s unique ability to
analyse data at any point within a cycle or dwell time
can be a significant advantage when evaluating certain
detection chemistries including molecular beacons.
PVIII-03 Exact quantification of gene amplification in archival tissue sections by laser-assisted
microdissection and real-time PCR
U Lehmann, S Glöckner, W Kleeberger, R von Wasielewski and H Kreipe
Institute of Pathology, Medizinische Hochschule Hannover, D-30625 Hannover, Germany
Gene amplification is one of the most important mechanisms
leading to deregulated gene expression in cancer. The exact
quantitative detection of this frequent genomic alteration in
solid tumors is hampered by admixture of non-neoplastic
bystander cells. In order to overcome this shortcoming and
to develop an objective quantification method, we have com-
bined laser-based microdissection of tumor cells with the
novel 5¢-exonuclease based real-time PCR-assay that
enables the highly reproducible exact quantification of
minute amounts of nucleic acids. As a model system, amplifi-
cation of the c-erb-B2/Her-2/neu gene and the adjacent
topoisomerase IIa gene were determined in paraffin-embed-
ded breast cancer tissue (n= 23) after immunohistochemi-
cal labelling and laser-based microdissection.
The quantitative assay was linear over a broad range
approaching the theoretical detection limit. 91% (21/23)
of the specimens were suitable for the PCR analysis. The
immunohistochemical labelling of cells did not interfere at
all with the quantitative PCR. The high sensitivity of real-
time PCR enabled the reliable and objective detection of
low level amplifications in as few as 50 cells from archival
tissue sections. In selected cases intratumor heterogene-
ity was analysed using areas of approx. 50–100 cells. In
addition, we have already started the systematic analysis
of gene amplification in DCIS of the breast to correlate
morphological classification systems with the results of
molecular analysis.
This novel approach, combining immunohistochemistry,
laser-microdissection and quantitative kinetic PCR, allows
morphology-guided studies in archival tissue specimens
and will enable the exact quantification of gene copy
numbers even in small and precancerous lesions.
PVIII-04 Screening for BRCA1 gene mutations by capillary electrophoretic REF-SSCP
P Kringen*, HG Eiken†, JC Pedersen*, S Egedal*, TE Ottesen*, K Berg*, KM Tveit‡ and TI Andersen*‡
Departments of *Medical Genetics and †Oncology, Ullevål University Hospital, N-0407 Oslo, ‡Center for Molecular Medicine,
Haukeland Hospital, N-5031 Bergen, Norway
The identification of novel mutations in large genes
requires efficient mutation-scanning techniques. Except
for DNA-sequencing and PTT (protein truncation test),
SSCP (single strand conformation polymorphism) is the
technique that has been the most extensively applied to
scan for mutations in the BRCA1-gene. In the present
study a capillary electrophoretic (CE) restriction endonu-
clease fingerprinting (REF) modification of the SSCP
technique was established for BRCA1 exon 11.
Samples containing a total of 16 known nucleotide
changes in BRCA1 exon 11 were examined. Exon 11 was
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PVIII-05 Hypervariable area in the 5¢ ¢ flanking region of GSTP1, previously reported as a minisatellite
repeat
V Nedelcheva Kristensen*, T Kristensen† and A-L Børresen-Dale*
*Department of Genetics, Institute of Cancer Research, The Norwegian Radium Hospital, Montebello 0310, Oslo, †Department of
Biochemistry, University of Oslo, Norway
Glutathione S transferases are dimeric molecules,
catalysing the conjugation of activated (acetylated, alky-
lated, hydroxylated, oxygenated) molecules of xenobiotics
to glutathione. Large deletions in the genes coding for
some of the enzymes (GSTM1, GSTT1) are known and
related to deficiency in conjugation of the metabolites of
xenobiotics. Alterations in glutathione metabolism have
been shown to have an important impact on the cytotoxic-
ity of various free radical-producing anticancer drugs, like
adriamycin. The overexpression of GSTP1 was shown to
be involved in the acquisition of resistance to anticancer
drugs like adriamycin, cisplatin, melphalan and etoposide.
Two polymorphisms in GSTP1 are known: a point muta-
tion in exon 5 with a possible functional role, leading to
changes in the kinetic properties of the enzyme, and a
repeat of AAAAT in the 5¢ untranslated region immedi-
ately upstream of an extensively methylated CpG island.
Poly AT-rich repeats are implicated as differential
enhancers of transcriptional activation. Here we report
that the repeat in the AT-rich area of the 5¢ untranslated
region is further degenerated by insertions of CAC, ATT
and other motifs, and describe a detailed analysis of the
polymorphism with a putative role in the regulation of
transcriptional activation.
amplified in four overlapping PCR-fragments. Aliquots of
labelled PCR products were submitted to digestion with
three or four fragment-specific restriction enzymes and
submitted to electrophoresis. Each sample was analysed
using (1) radioactive labelling and polyacrylamide gel elec-
trophoresis (PAGE) and (2) fluorochrome labelling and
capillary electrophoresis in an ABI 310 sequencer.
Samples giving abnormal electropherograms were ream-
plified and sequenced to identify the exact nature of the
nucleotide change. All of the 16 known nucleotide
changes could be detected by method 1. The aberrant
band indicating the presence of one of the mutations
(G484X) was, however, difficult to reproduce. All
nucleotide changes but G484X were detected by fluo-
rochrome-labelled CE-REF-SSCP (method 2). This
method appeared as the faster and technically more con-
venient of the two.
CE-REF-SSCP was chosen as the mutation-scanning
technique in our further BRCA1 studies. A series consist-
ing of 75 affected members of Norwegian breast cancer
families was first screened for a set of Norwegian BRCA1
mutations using restriction enzyme-based tests. The
samples were then screened for novel mutations in exon
11 by CE-REF-SSCP. The results of this mutation screen-
ing will be presented.
PVIII-06 Comparative genomic hybridisation analysis of myoepithelial carcinoma of the breast
C Jones*, MP Foschini†, R Chaggar‡, Y-J Lu¶, D Wells§, JM Shipley¶, V Eusebi† and SR Lakhani*
*Departments of Histopathology, §Obstetrics and Gynaecology, and ‡The Ludwig Institute for Cancer Research, University
College London, UK, †Sezione di Anatomia, Istologia e Citologia Patologica ‘M. Malpighi’, Università di Bologna, Italy, ¶Section
of Cell and Experimental Pathology, The Institute for Cancer Research, Surrey, UK
Although there appears to be a common stem cell for the
two epithelial cell types in the breast, the majority of
breast cancers exhibit a luminal phenotype. Pure myoep-
ithelial carcinomas are rare. We report our findings of
genetic alterations in these tumours. We have analysed
10 cases of pure spindle cell myoepithelial carcinomas
using laser capture microdissection and comparative
genomic hybridisation. The mean number of changes was
2.1 (range 0–4), compared to a mean of 8.6 (range
3.6–13.8) in unselected ductal carcinomas. Common
alterations included loss at 16q (3/10 cases), 17p
(3/10), 11q (2/10) and 16p (2/10), regions also com-
monly deleted in ductal carcinomas. The single case in
which both pure myoepithelial carcinoma and invasive
ductal carcinoma was present showed two alterations in
the myoepithelial tumour (losses at 17p and 17q), while
the invasive ductal component showed fourteen alter-
ations (5 gains and 9 losses), including loss at 17p. The
sharing of 17p loss in myoepithelial and ductal carcinoma
is consistent with a common stem cell model in the
breast. The relatively few genetic alterations in otherwise
aggressive neoplasms suggests that myoepithelial
tumours may be a good model for the delineation of
genes important in breast tumorigenesis.PVIII-07 Genetic alterations in ductal carcinoma in situ and invasive carcinoma of the breast
E Robanus-Maandag, C Bosch, C Vos, H Peterse and M van de Vijver
The Netherlands Cancer Institute, Amsterdam, The Netherlands
Several histological classifications propose a subdivision
of ductal carcinoma in situ (DCIS) into well-, intermedi-
ately, and poorly differentiated subtypes. The use of bio-
logical parameters (extent of immunopositivity,
proliferation rate, and aneuploidy) facilitates such subdivi-
sion. Moreover, determination of genetic alterations can
contribute to the identification of the different DCIS sub-
types. Our recent data indicate that inactivation of an
unidentified tumor suppressor gene on chromosome 16q
is involved in the development of most well and intermedi-
ately differentiated DCIS. Moreover, amplification and
inactivation of various genes on chromosome 17 are
implicated in the development of poorly differentiated
DCIS. These data show that there is a genetic basis for
the classification of DCIS in a well and poorly differenti-
ated type, and support the evidence of independent
genetic routes to develop a specific type of carcinoma in
situ of the breast.
Our study has revealed that the spectrum of genetic alter-
ations in the in situ tumors is comparable to that of the inva-
sive carcinomas. However, the frequencies of the individual
genetic alterations differ significantly between the two tumor
categories. As most invasive carcinomas also contain an in
situ component, we want to compare the genetic alterations
in both components of the same tumor and, in this way,
identify the genetic alterations that are involved in the pro-
gression from the in situ to the invasive stage. We have
microdissected the invasive and adjacent in situ component
of paraffin-embedded invasive breast carcinomas with a rel-
atively large in situ component, isolated DNA, and per-
formed comparative genomic hybridization (CGH).
PVIII-08 Identification of two novel breast cancer associated genes by the differential display method
N Maass*†, K Nagasaki†, VR Jacobs* and W Jonat*
*OB/GYN, Department of Oncology, University of Kiel, Germany, †National Cancer Center, Tokyo, Japan
Using the Differential Display (DD) technique we identified
two novel genes that are over-expressed in human breast
cancer cells compared to various other human cancer cells
which were screened for differentially expressed genes.
Messenger RNAs were transcribed, followed by PCR
amplification and visualisation of the cDNA subpopulation
by polyacrylamide gel electrophoresis. Eight human tumor
cell lines where used to select differentially expressed
genes by DD. Cloning and sequencing of two overex-
pressed cDNA clones in MCF 7 breast cancer cells identi-
fied two novel genes. By FISH analysis one gene was
mapped on the X chromosome and therefore designated
‘breast cancer associated gene on chromosome X’ (BG-
X). The second novel gene, designated DAM1 (DNA ampli-
fied in mammary carcinoma) was mapped on the chromo-
some 1p13.3–21 region, which is frequently altered in
human breast cancer. Northern blot analysis of BG-X
revealed ubiquitous expression in normal human tissue (eg
kidney, pancreas, small intestine, stomach, colon, ovary,
liver, brain, heart) and in breast cancer cells (7/7), but no
expression in several human cancer cells (carcinomas of
pancreas (1/9), stomach (0/7) and prostate (0/4)). Using
an enhanced green fluorescent protein (EGFP) assay, the
EGFP-BG-X-fusion protein was localised in the cell
nucleus. Our data present two novel genes with strong
expression in human breast cancer cells and down-regula-
tion in several other cancer cell lines.
PVIII-09 Expression profiling of BRCA1 associated breast tumors
EMJJ Berns, IL van Staveren, L Verhoog, JA Foekens and JGM Klijn
Department of Medical Oncology, Division of Endocrine Oncology, JNI Be424, PO Box 1738, 3000DR Rotterdam The Netherlands
BRCA1-associated breast tumours frequently show
unfavourable features, ie poor differentiation, high prolifera-
tion indices, aneuploidy, ER- and PgR negativity, and TP53
positivity. These data are based on single gene analysis.
Expression arrays, however, allow for the simultaneous inves-
tigation of multiple genes. We have used Atlas Human
Cancer cDNA Expression Arrays (Clontech), on which 588
cancer-related genes are spotted, for an exploratory analysis.
Profiles of one cell line and six tumours from patients with an
inherited  BRCA1 gene mutation were weighed against
those from 15 patients without a family history who had
similar clinico-pathological characteristics which are col-
lected in our computerised database system. Total RNA iso-
lation was performed according to standard procedures.
RNAs were used to synthesise 32P-radiolabeled cDNA for
hybridisation to the cancer cDNA expression arrays, accord-
ing to the manufacturer’s instructions. Data were acquired
and quantified using the Molecular Dynamics PhosphoIm-
ager and ImageQuant software (Molecular Dynamics, Sun-
nyvale, USA). The levels of the lowest and highest expressed
genes differed at 100- or 1000-fold. In an exploratory analy-
sis we have considered only the upper 30% ranking of the
signals for each tumor sample as ‘high’ expression (H), and
the data were dichotomised: high (H) vs low (L).
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In this pilot study on 6 BRCA1 and 15 sporadic tumours
we observed that 14 genes showed high (H) expression
levels, in all cases. Furthermore, 396 genes showed a
heterogeneous expression pattern (including the EGF-R,
MYC, p16, HER2/neu and uPA). These heterogeneous
expression levels are consistent with our previous
studies on breast cancer. Ten genes are mostly
expressed at an increased level in BRCA1 tumours
when compared to sporadic tumours. Interestingly the
majority of these genes are known to play a role in cell
adhesion, motility and invasion. Although the series of
breast tumours analysed is relatively small, we were able
to identify genes whose expression appears differential
in BRCA1 and sporadic breast tumours. Cluster analy-
sis, which allows for grouping of tumors and genes
according to similar patterns of expression, revealed that
the expression profiles of 5 out of 6 BRCA1-associated
tumors are clustered in one arm. Extension of the number
of genes and tumour samples will reveal additional
genes.
PVIII-10 Transcript profiles and genotyping of cancer tissue
C Malmqvist*, M Sievertzon*, A Gustafsson*, A Holmberg*, M Larsson*, A Alderborn†, M Uhlén* and J Lundeberg*
*Department of Biotechnology, KTH, Royal Institute of Technology, Stockholm, †Pyrosequencing AB, Uppsala, Sweden
Gene expression profiling has become one of the most
attractive approaches to elucidate gene function. For these
purposes, hybridization methods and SAGE have been the
most commonly used techniques. We have developed an
alternative strategy for cDNA tag analysis that results in a
quantitative estimate of gene expression. The strategy
relies on generation of 3¢-tagged cDNA libraries and a new
non-gel-based high throughput DNA-sequencing principle,
pyrosequencing. Pyrosequencing is based on a sequenc-
ing by synthesis strategy in which single specific
nucleotides are added to an extension substrate in the
presence of a DNA polymerase. Incorporation is detected
in real-time through an enzymatic cascade that produces a
quantitative light signal, measured by a CCD-camera. A
microtiter format is used, allowing sequencing of 96
samples within 40 min. In total, 2000 clones from a human
tissue model system have been analysed by both conven-
tional DNA sequencing and pyrosequencing. For the analy-
sis of only a few cells, a cDNA amplification step, keeping
the relative transcript levels, is used in the generation of the
libraries. Furthermore, an SNP analysis technique based on
pyrosequencing and the p53 tumor suppressor gene has
been developed, that will allow correlation between expres-
sion and genotype of cancer tissue. The quantitative gene
expression profiles from compared libraries are visualized
by virtual chip technology.
PVIII-11 Relation of gene expression-based tumor subclasses to clinical phenotypes
T Sørlie, CM Perou, PE Lønning, PO Brown, D Botstein and A-L Børresen-Dale
The Norwegian Radium Hospital, Oslo, Norway
Gene expression analysis by cDNA microarrays is a pow-
erful tool for characterizing the variation in transcriptional
programs in cells and tissues. We have analysed surgi-
cal specimens from 40 human breast tumors using
cDNA microarrays representing 8000 human genes.
From 20 of the tumors, pairs of biopsies were obtained
both before and after a 16-week course of doxorubicin
chemotherapy. Two of the tumors were paired with
lymph node metastases. Expression patterns reflecting
specific features of physiological variation and cellular
composition of the tumors provided unique molecular
portraits of each tumor. Different clusters of co-
expressed genes, like the estrogen receptor, the ERBB2
gene and basal cell specific genes, were used to further
subclassify the tumors. The different subgroups, identi-
fied by unique expression patterns, were associated with
clinical parameters such as overall survival. Also, the
TP53 mutation status in the tumors was associated with
disease outcome within these subclasses. Although the
sample size in any of the subgroups is too small to
support any statistically robust tests, our preliminary
results show the potential of gene expression-based
subtyping of breast cancer in predicting clinical behav-
iour and therapy response.